Anti-cd40 monoclonal antibody

ABSTRACT

An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of application Ser. No.09/844,684 filed on Apr. 27, 2001, application Ser. No. 10/040,244 filedOct. 26, 2001 and PCT/JP02/04292 having an international filing date ofApr. 26, 2002, which designated the United States of America. Thisapplication and application Ser. No. 10/040,244 are also each acontinuation-in-part of application Ser. No. 09/844,684. Thisapplication also claims priority under 35 U.S.C. §119(a) on JapanesePatent Applications Nos. 2001-142482 filed May 11, 2001 and 2001-310535filed Oct. 5, 2001. The entire contents of all of the above-identifiedapplications are hereby incorporated by reference.

TECHNICAL FIELD

The present invention relates to an antibody or a functional fragmentthereof that recognizes a human CD40 antigen present on the surface ofhuman B cells, dendritic cells (DC) and the like. Specifically, thepresent invention relates to an anti-human CD40 antibody or a functionalfragment thereof that is substantially antagonistic to a human CD40antigen on the dendritic cell (DC) surface, and an agonistic anti-humanCD40 antibody or a functional fragment thereof that is expected to havea therapeutic effect higher than those of conventional anti-human CD40antibodies.

BACKGROUND ART 1. CD40

CD40 is an antigen with a molecular weight of 50 kDa that is present onthe cell membrane surface. CD40 is expressed on B cells, dendritic cells(DC), certain types of cancer cells, and thymic epithelial cells. CD40is known to play a key role in proliferation and differentiation of Bcells and DC. CD40 has been identified as an antigen that is expressedon the human B cell surface (E. A. Clark et. al., Proc. Natl. Acad. Sci.USA 83: 4494, 1986, I. Stamenkovic et. al., EMBO J. 8:1403, 1989). Basedon the amino acid sequence homology, CD40 is thought to be a member ofthe TNF receptor family, to which a low affinity NGF receptor, TNFreceptor, CD27, OX40, CD30 and the like belong. The gene of a ligand(CD40L) for human and mouse CD40 has been cloned recently, revealingthat it is a type II membrane protein, and is expressed on activatedCD4+T cells. It has also been shown that CD40L introduces strongactivation signals into human and mouse B cells.

The expression of CD40 has been confirmed more often on dendritic cellsthan on B cells, so that it has become clear that CD40 plays animportant role. The binding of CD40 with CD40L causes the activation ofantigen-presenting cells (APC). Specifically, it enhances the expressionof co-stimulation molecules such as CD80 (B7-1) and CD86 (B7-2), or theproduction of IL-12 (Caux, C., et al.: Activation of human dendriticcells through CD40 cross-linking. J. Exp. Med., 180:1263, 1994), (Shu,U., et al: Activated T cells induce interleukin-12 production bymonocyte via CD40-CD40 ligand interaction. Eur. J. Immunol. 25: 1125,1995). Dendritic cells show strong antigen-presenting ability, and havestrong helper T (Th) cell-activating ability. Furthermore, it is thoughtthat dendritic cells control the differentiation of naive Th cells intoTh1 or Th2 cells. When dendritic cells (DC1) are made to mature byculturing peripheral blood monocytes that are myeloid dendritic cells inthe presence of GM-CSF and IL-4 and using CD40L, the DC1 in vitro arecapable of producing IL-12, stimulate and activate allo-naive Th cells,and thus induce IFNγ-producing T cells (specifically, promotesdifferentiation into Th1). Since this action is inhibited by anti-IL-12antibodies, the reaction may be mediated by IL-12. On the other hand,when lymphocyte-dendritic cells (DC2) are prepared by culturinglymphatic tissue T regions or plasmacytoid T cells present in peripheralblood with IL-3 and CD40 ligands, DC2 are incapable of producing IL-12,stimulate and activate allo-naive Th cells, induce IL-4-producing Tcells, and thus promote differentiation into Th2. It is thought that Th1cells are involved in the activation of cellular immunity, and Th2 cellsare involved in enhancement of the ability for humoral immunity as wellas the suppression of the ability for cellular immunity. Cytotoxic Tcells (CTL) activated with the help of Th1 cells can remove causativefactors (many viruses, Listeria monocytogenes, tubercle bacillus,toxoplasma protozoa and the like) multiplying in the cytoplasm and tumorcells.

It has been shown that anti-CD40 monoclonal antibodies that recognizeCD40 expressed on the membrane surfaces exert a variety of biologicalactivities on B cells. Anti-CD40 monoclonal antibodies are largelyclassified into agonistic and antagonistic antibodies impacting theinteraction between CD40 and CD40L.

2. Agonistic Antibody

The activation of B cells is known as an action of agonistic antibodies.For example, anti-CD40 antibodies have been reported to induce celladhesion (Barrett et al., J. Immunol. 146: 1722, 1991; Gordon et al., J.Immunol. 140: 1425, 1988), enhance cell size (Gordon et al., J. Immunol.140: 1425, 1988; Valle et al., Eur. J. Immunol. 19: 1463, 1989), inducethe division of B cells that are activated only with anti-IgMantibodies, anti-CD20 antibodies or phorbol ester (Clark and Ledbetter,Proc. Natl. Acad. Sci. USA 83: 4494, 1986; Gordon et al., LEUCOCYTETYPING III. A. J. McMicheal ed. Oxford University Press. Oxford, p. 426;Paulie et al., J. Immunol. 142: 590, 1989), induce the division of Bcells in the presence of IL4 (Valle et al., Eur. J. Immunol. 19: 1463,1989; Gordon et al., Eur. J. Immunol. 17: 1535, 1987), induce theexpression of IgE (Jabara et al., J. Exp. Med. 172: 1861, 1990; Gascanet al., J. Immunol. 147: 8, 1991), IgG and IgM (Gascan et al., J.Immunol. 147: 8, 1991) of cells stimulated with IL-4 and culturedwithout T cells, enhance the secretion and the on-the-cell expression(Challa A, Allergy, 54: 576, 1999) of soluble CD23/Fcε RII from B cellsby IL-4 (Gordon and Guy, Immunol. Today 8: 339, 1987; Cairns et al.,Eur. J. Immunol. 18: 349, 1988), and promote IL-6 production (Clark andShu, J. Immunol. 145: 1400, 1990). Furthermore, it has been reportedthat B cell clones are established from human primary culture B cells byadding IL-4 and anti-CD40 antibodies in the presence of CDw32+ adhesioncells (Bancherau et al., Science 241:70, 1991), and the inhibition ofthe apoptosis of germinal center cells is mediated by CD40, regardlessof the function of antigen receptors (Liu et al., Nature 342: 929,1989). As described above, CD40 has been identified as an antigenexpressed on the human B cell surface. Thus, most of the isolatedantibodies have been evaluated mainly using function to induce theproliferation and differentiation of human B cells and activity toinduce cell death in cancer cells as indicators (Katira, A. et. al.,LEUKOCYTE TYPING V. S. F. Schlossossman, et al. eds. p. 547. OxfordUniversity Press. Oxford, W. C. Flansow et al., LEUKOCYTE TYPING V. S.F. Schlossossman, et al. eds. p. 555. Oxford University Press. Oxford,J. D. Pound et al., International Immunology, 11: 11, 1999).

Anti-CD40 antibodies were shown to cause the maturation of DC (Z. H.Zhou et. al., Hybridoma, 18: 471 1999). Moreover, the role of CD4T cellsin antigen-specific CD8T cell priming has been reported to activate DCvia CD40-CD40L signaling. It was shown that the role of CD4 helper Tcells in activation of dendritic cells (DC) can be replaced by that ofanti-CD40 monoclonal antibodies (mAb) (Shoenberger, S. P., et al.:T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40Linteractions. Nature, 480, 1998). Furthermore, it was shown in mice thatthe organism can be protected not only from tumor cells expressing CD40but also from tumor cells not expressing the same by the administrationof anti-CD40 antibodies (French, R. R., et. al.: CD40 antibody evokes acytotoxic T-cell response that eradicates lymphoma and bypasses T-cellhelp. Nature Medicine, 5, 1999).

Most antibodies reported to date have not been isolated using the effecton DC as an indicator. However, in terms of the modification of DCfunctions, antibodies selected by their action on B cells are likely tobe insufficient as therapeutic agents. It was reported that amongmonoclonal antibodies against mouse CD40, there are clones that react toDC, but do not react to vascular endothelial cells, and, conversely,clones that do not react to DC, but react to vascular endothelial cells,depending on epitopes that the antibodies recognize (Van Den Berg, T K,et. al., Immunology, 88: 294, 1996). It is also assumed that the bindingand action of human CD40 antibodies to DC differ depending on epitopes.

It is known that anti-CD40 antibodies or CD40 ligands can suppress theproliferation of CD40-expressing lymphoma cell lines and thus can inducethe cell death (Funakoshi S et al., Blood, 83: 2782, 1994; Funakoshi Set al., Journal of Immunotherapy, 19, 93, 1996; Z. H. Zhou et. al.,Hybridoma, 18: 471 1999; and Joseph A et al., Cancer Research, 60: 3225,2000). What is interesting about agonistic antibodies is that thefunction of the antibody does not always coincide always with that ofCD40L. Action to activate B cells does not also coincide with action tosuppress B cell tumor growth. It is desired to develop antibodies havingboth DC-activating ability and tumor cell proliferation-suppressingaction. Moreover, among agonistic antibodies, both antibodies thatinhibit and those that do not inhibit the binding of CD40L to CD40 arepresent (Challa A et al., Allergy, 54: 576, 1999). For example,antibodies produced by G28-5 (ATCC No. HB-9110) compete with CD40L, sothat there is no effect resulting from the combined use with CD40L. Thedegree of activation of CD40-expressing cells differs depending onantibodies. Even when antibodies exhibit independently weak agonisticactivity, the combined use of the antibodies with CD40 ligands may moresignificantly promote the activity in the presence of the antibodies,than the activity resulting from CD40 ligands alone. In contrast, evenwhen antibodies exhibit independently agonistic activity, inhibition ofCD40 ligands may lower the activity in the presence of the antibodies toa greater extent than the activity resulting from CD40 ligands alone(Pound et al., International Immunology, 11:11, 1999). It was shown thatwith antibodies that do not compete with CD40 ligands, strongersuppression of proliferation can be achieved in the presence of CD40ligands, although the tumor cell proliferation-suppressing action of theantibody itself is weak (Joseph A et al., Cancer Research, 60: 3225,2000). Accordingly, it is desired to develop antibodies that bind toCD40 to suppress independently cell proliferation, but that do notinhibit the binding of CD40 ligands to CD40. By taking full advantage ofsuch characteristics, there is a possibility of developing a therapeuticagent that is more efficient than a soluble CD40L. For example, thesoluble CD40L is activated by binding with CD40, and at the same time,it suppresses the function of CD40L present in vivo. An antibody thatdoes not compete with CD40L, does not cause such suppression, and hasbetter therapeutic effects can be expected by synergistic effect.

3. Antagonistic Antibody

In the meantime, as described above, it is expected that because CD40plays an important role in immune reaction, therapeutic agents forimmune suppression upon organ transplantation and against autoimmunedisease can be developed by inhibiting the binding of CD40 with itsligand. Sawada-Hase et al., have reported that the proportion of cellsstrongly expressing CD40 was increased in the peripheral blood monocytesof Crohn's disease patients. However, antibodies that inhibit thebinding of CD40 with its ligand have not been well understood Forexample, such antibodies that inhibit the binding may be effective forthe functional analysis of CD40, and therapy against disease, for whichactivation of CD40 is required. Moreover, antibodies that inhibit CD40ligands have been also shown to have the potential of being effective asagents against diseases with which the binding of CD40 with CD40 ligandsis involved. However, it has been reported that CD40L is expressed inactivated blood platelets (V. Henn et. al., Nature 391: 591, 1998).Thus, it has been reported that there is a risk of causing thrombi, ifanti-CD40L antibodies are used as a therapeutic agent (T. Kawai et. al.,Nat. Medi. 6: 114, 2000). From such a point of view, antibodies againstCD40 can be expected to be safer than anti-CD40L antibodies, as anantibody therapeutic agent that inhibits the binding of CD40 with itsligand. Anti-CD40 antibodies are required to suppress the binding ofCD40L to CD40, and not to activate CD40 by the antibody itself.

Although a huge number of studies have been conducted in the pastconcerning antibodies that bind specifically to human CD40 and suppressthe binding of CD40L to CD40 without activating CD40, only a singlecase, that is a mouse anti-human CD40 antibody, named 5D12, has beenreported (J. Kwekkeboom et al., Immunology 79: 439, 1993). In addition,it has not been known whether or not antibodies showing neutralizationactivity for B cells can also show the same for DC that is, if theantibodies can neutralize the action of CD40 ligands. Furthermore, ithas been reported that the action of biotinylated anti-mouse CD40antibodies is enhanced by cross-linking with avidin (Johnson et al., EurJ Immunol, 24: 1835, 1994). We enhanced the action of soluble CD40ligands against a B cell line (Ramos cells) using antibodies (M2)against tags (FLAG), which had been previously provided by geneticengineering techniques to the soluble ligands, and measured theneutralization activity. Thus, we confirmed that 5D12 (ATCC No.HB-11339) exhibits only slight neutralization activity.

We have newly found that 5D12, an antagonistic antibody, has agonisticactivity on its own, as a result of cross-linking even in the absence ofCD40L. Conventionally, it has been reported that the action of mouseCD40 antibodies is enhanced by cross-linking of biotin with avidin(Johnson et al., Eur J Immunol, 24: 1835, 1994). Furthermore, it hasbeen known that solid-phasing of CD40 antibodies usinganti-immunoglobulin antibodies solid-phased on a plate leads to anincrease in activity to suppress the proliferation of tumor cells. Thishas been thought to be an effect resulting from solid-phasing. However,it has not been known that when anti-immunoglobulin antibodies are addedto a culture solution for cross-linking of anti-CD40 antibodies, it maybecome possible even for antagonistic antibodies to show agonisticactivity. If antibodies to be used for therapy have antigenicity, acompletely opposite effect may occur, such that antibodies which bind toCD40 antibodies in a human body are produced, and with which CD40antibodies are cross-linked, so that activity seemingly the same as thatof CD40 ligands is produced. Accordingly, in view of the safety of atherapeutic agent, it is very important to keep the antigenicity ofantibodies at a low level. Consider a case wherein a therapeutic agentis developed by humanization technology based on the sequence of avariable region of a mouse antibody. Since humanized antibodies areknown to have immunogenicity, anti-humanized anti-CD40 antibodies may beproduced after administration. Specifically, there may be a risk thatthe antibodies would become agonistic antibodies. Even if theantigenicity is low, anti-CD40 antibodies may be cross-linked withantibody receptors (FcR). From these points, a preferred antagonisticantibody is a human antibody, which binds specifically to CD40,suppresses the binding of CD40L, and does not activate CD40 even bycross-linking, and exhibits weak binding to FcR.

SUMMARY OF THE INVENTION

As described above, the functions of DC have been increasingly analyzedrecently, so that CD40 has begun to be recognized as a gene important incontrolling the functions of DC. Starting from this background, thepurpose of the present invention is to provide by employing anevaluation system using DC, an anti-human CD40 antibody or a functionalfragment thereof, which is substantially antagonistic also to a humanCD40 antigen on the dendritic cell (DC) surface, and an agonisticanti-human CD40 antibody or a functional fragment thereof that isexpected to have a therapeutic effect higher than that of theconventional anti-human CD40 antibody.

As a result of intensive studies concerning the preparation ofantibodies against human CD40, we have completed the present inventionby succeeding in producing a novel agonistic antibody and antagonisticantibody that are thought to have a therapeutic effect against diseasehigher than that of the conventionally known anti-CD40 antibody. Thatis, the present invention is as follows.

(1) An antibody against a human CD40, or a functional fragment thereof,having at least one property selected from the following properties (a)to (f) of:(a) acting on dendritic cells to produce IL-12 in the presence of LPSand IFNγ;(b) having activity to act on dendritic cells causing the cells tomature, which is higher than that of a G28-5 antibody;(c) having activity to promote an established B cell line to expressCD95, which is higher than that of the G28-5 antibody;(d) having activity to suppress the proliferation of an established Bcell line, which is higher than that of the G28-5 antibody;(e) inducing cell death of an established B cell line; and(f) not inhibiting the binding of CD40 ligands to CD40.(2) The above antibody or the functional fragment thereof of the presentinvention, wherein the maturation of dendritic cells is performed at aconcentration of 20 μg/ml or less. In addition, the antibody or thefunctional fragment thereof promote the established B cell line toexpress CD95 at the antibody concentration of 20 μg/ml or less. Examplesof the established B cell line include Ramos, HS-Sulton or the like.(3) Furthermore, the above antibody or the functional fragment thereofof the present invention leads to the production of 100 pg/ml or moreIL-12 when the antibodies with a concentration of 0.1 μg/ml or more areadded to dendritic cells with a concentration of 1×10⁶ cells/ml, and theproduction of 1000 pg/ml or more, preferably 10000 pg/ml or more IL-12when the antibodies with a concentrationof 1 μg/ml or more are added.(4) Furthermore, within the antibody concentration range between 0.01μg/ml and 10 μg/ml, the above antibody or the functional fragmentthereof of the present invention, promoting the established B cell line(Ramos cell) to express CD95 with approximately 2 to 3 times or moregreater effectiveness than that expressed by a G28-5 antibody as acontrol. For example, with an antibody concentration of 0.01 μg/ml, theexpression is promoted with approximately 2 to 6 times or more greatereffectiveness than that expressed by the G28-5 antibody as a control.With an antibody concentration of 0.1 μg/ml, the expression is promotedwith approximately 2 to 7 times or more greater effectiveness than thatexpressed by the G28-5 antibody as a control. With an antibodyconcentration of 1 μg/ml, the expression is promoted with approximately2 to 7 times or more greater effectiveness than that expressed by theG28-5 antibody as a control. With an antibody concentration of 10 μg/ml,the expression is promoted with approximately 2 to 6 times or moregreater effectiveness than that expressed by the G28-5 antibody as acontrol.(5) An antibody or a functional fragment thereof, having the amino acidsequences of a heavy chain variable region and a light chain variableregion of an antibody that is produced by a hybridoma KM302-1 (AccessionNo: FERM BP-7578), KM341-1-19 (Accession No: FERM BP-7759), 2105(Accession No: FERM BP-8024) or F1-102 (Accession No: ATCC PTA-3337).

Name Accession No. Deposition date Deposited with: KM302-1 FERM BP-7578May 9, 2001 International Patent KM341- FERM BP-7759 Sep. 27, OrganismDepositary, 1-19 2001 National Institute of 2105 FERM BP-8024 Apr. 17,2002 Advanced Industrial Science and Technology (Central 6, 1-1-1,Higashi, Tsukuba, Ibaraki, Japan) F1-102 ATCC Apr. 24, 2001 AmericanType Culture PTA-3337 Collection (10801 University Blvd. Manassas,Virginia, 20110-2209, U.S.A.)(6) An antibody or a functional fragment thereof, having amino acidsequences of the mature portions of a heavy chain variable region and alight chain variable region of the antibody produced by a hybridomaF2-103, which are respectively encoded by plasmid DNAs with AccessionNos. ATCC PTA-3302 and ATCC PTA-3303; a heavy chain variable region anda light chain variable region of the antibody produced by a hybridomaF5-77, which are respectively encoded by plasmid DNAs with AccessionNos. ATCC PTA-3304 and ATCC PTA-3305; or a heavy chain variable regionand a light chain variable region of the antibody produced by ahybridoma F5-157, which are respectively encoded by plasmid DNAs withAccession Nos. ATCC PTA-3306 and ATCC PTA-3307.

Name Accession No. Deposition date Deposited with: F2-103 ATCC Apr. 19,2001 American Type Culture heavy chain PTA-3302 Collection (10801(F2-103-H) University Blvd. F2-103 light ATCC Apr. 19, 2001 Manassas,Virginia, chain PTA-3303 20110-2209, U.S.A.) (F2-103-L) F5-77 heavy ATCCApr. 19, 2001 chain PTA-3304 (F5-77-H) F5-77 light ATCC Apr. 19, 2001chain PTA-3305 (F5-77-L) F5-157 ATCC Apr. 19, 2001 heavy chain PTA-3306(F5-157-H) F5-157 light ATCC Apr. 19, 2001 chain PTA-3307 (F5-157-L)(7) An antibody or a functional fragment thereof, laving amino acidsequences ofthe mature portions of a heavy chain variable region and a light chainvariable region of the antibody produced by a hybridoma KM34′-1-19,which are respectively represented by SEQ ID NOS: 28 and 30; a heavychain variable region and a light chain variable region of the antibodyproduced by a hybridoma 2105, which are respectively represented by SEQID NOS: 32 and 34; a heavy chain variable region and a light chainvariable region of the antibody produced by a hybridoma 110, which arerespectively represented by SEQ ID NOS: 36 and 38; a heavy chainvariable region and a light chain variable region of the antibodyproduced by a hybridoma 115, which are respectively represented by SEQID NOS: 40 and 42; a heavy chain variable region and a light chainvariable region of the antibody produced by a hybridoma KM643-4-11,which are respectively represented by SEQ ID NOS: 52 and 54; a heavychain variable region and a light chain variable region of the antibodyproduced by a hybridoma F2-103, which are respectively represented bySEQ ID NOS: 60 and 62; or a heavy chain variable region and a lightchain variable region of the antibody produced by a hybridoma F5-77,which are respectively represented by SEQ ID NOS: 64 and 66.(8) An antibody or a functional fragment thereof, having amino acidsequences of the mature portions of a heavy chain variable region and alight chain variable region that are encoded by nucleic acid sequencesisolated from a hybridoma KM341-1-19, which are respectively representedby SEQ ID NOS: 27 and 29; a heavy chain variable region and a lightchain variable region that are encoded by nucleic acid sequencesisolated from a hybridoma 2105, which are respectively represented bySEQ ID NOS: 31 and 33; a heavy chain variable region and a light chainvariable region that are encoded by nucleic acid sequences isolated froma hybridoma 110, which are respectively represented by SEQ ID NOS: 35and 37; a heavy chain variable region and a light chain variable regionthat are encoded by nucleic acid sequences isolated from a hybridoma115, which are respectively represented by SEQ ID NOS: 39 and 41; aheavy chain variable region and a light chain variable region that areencoded by nucleic acid sequences isolated from a hybridoma KM643-4-11,which are respectively represented by SEQ ID NOS: 51 and 53; a heavychain variable region and a light chain variable region that are encodedby nucleic acid sequences isolated from a hybridoma F2-10)₃, which arerespectively represented by SEQ ID NOS: 59 and 61; or a heavy chainvariable region and a light chain variable region that are encoded bynucleic acid sequences isolated from a hybridoma F5-77, which arerespectively represented by SEQ ID NOS: 63 and 65.(9) An antibody against a human CD40, or a functional fragment thereof,having at least one property selected from the following properties (g)to (j) of:(g) neutralizing the action of ligands on CD40;(h) neutralizing or alleviating one or more effects that ligands, whichare for CD40 on an established B cell line, have on CD40-expressingcells, and having agonistic action on CD40 on the above established Bcell line weaker than that of 5D12 due to cross-linking byanti-immunoglobulin antibodies;(i) alleviating or neutralizing the action of CD40 ligands on theestablished B cell line to increase CD95 expression; and(j) having antagonistic action on CD40 expressed on dendritic cells.(10) The antibody or the functional fragment of (9) above can suppressthe expression of CD95 in Ramos cells to a level approximately 10% orless than that of a control, when antibodies with a concentration of 0.1μg/ml are added to the Ramos cells with a concentration of 1×10⁶cells/ml supplemented with a saturated amount of CD40L-expressing cells;can suppress the expression of CD95 in Ramos cells to the same level asthat of a negative control, when the antibodies with a concentration of1 μg/ml are added; and can suppress the expression of CD95 in the Ramoscells to the same level as that of the negative control, when theantibodies with a concentration of 10 μg/ml are added.(11) The antibody or the functional fragment thereof of (9) above,wherein the proliferation of tonsillar B cells is suppressed in vitro byapproximately 80 to 95% or more, when the antibodies with aconcentration between 0.001 μg/ml and 10 μg/ml are added to 1×10⁵tonsillar B cells supplemented with soluble CD40L (1 μg/ml). Forexample, when the antibodies with a concentration between 0.01 μg/ml and10 μg/ml are added, the proliferation of tonsillar B cells is suppressedby approximately 95% or more. In particular, when the antibodies with aconcentration of 0.001 μg/ml are added, the proliferation of tonsillar Bcells is suppressed by approximately 80% or more.(12) An antibody or a functional fragment thereof, having amino acidsequences of a heavy chain variable region and a light chain variableregion of the antibody produced by a hybridoma KM281-1-10 (Accession No:FERM BP-7579), 4D11 (Accession No: FERM BP-7758) or F4-465 (AccessionNo: ATCC PTA-3338).

Name Accession No. Deposition date Deposited with: KM281-1-10 FERMBP-7579 May 9, 2001 International Patent 4D11 FERM BP-7758 Sep. 27, 2001Organism Depositary, National Institute of Advanced Industrial Scienceand Technology (Central 6, 1-1-1, Higashi, Tsukuba, Ibaraki, Japan)F4-465 ATCC Apr. 24, 2001 American Type PTA-3338 Culture Collection(10801 University Blvd. Manassas, VA 20110-2209, U.S.A.)(13) An antibody or a functional fragment thereof, having amino acidsequences of the mature portions of a heavy chain variable region and alight chain variable region of the antibody produced by a hybridomaKM281-1-10, which are respectively represented by SEQ ID NOS: 44 and 46;a heavy chain variable region and a light chain variable region of theantibody produced by a hybridoma 4D11, which are respectivelyrepresented by SEQ ID NOS: 48 and 50; or a heavy chain variable regionand a light chain variable region of the antibody produced by ahybridoma F4-465, which are respectively represented by SEQ ID NOS: 56and 58.(14) An antibody or a functional fragment thereof, having amino acidsequences of the mature portions of a heavy chain variable region and alight chain variable region that are encoded by nucleic acid sequencesisolated from a hybridoma KM281-1-10, which are respectively representedby SEQ ID NOS: 43 and 45; a heavy chain variable region and a lightchain variable region of an antibody produced by a hybridoma 4D11, whichare respectively represented by SEQ ID NOS: 47 and 49; or a heavy chainvariable region and a light chain variable region that are encoded bynucleic acid sequences isolated from a hybridoma F4-465, which arerespectively represented by SEQ ID NOS: 55 and 57.(15) Examples of the antibody or the functional fragment thereof of (1)to (14) above include human antibodies.(16) A pharmaceutical composition, containing as an active ingredientthe antibody or the functional fragment thereof of any one of (1) to(15) above.(17) An immunopotentiating agent, anti-tumor agent or anti-autoimmunedisease agent, containing as an active ingredient the antibody or thefunctional fragment thereof of any one of (1) to (8) above.(18) An immunosuppressive agent, anti-autoimmune disease agent,therapeutic agent against allergies or therapeutic agent against bloodcoagulation factor VIII-inhibiting syndrome, containing as an activeingredient the antibody or the functional fragment thereof of any one of(9) to (14) above.(19) Here, an epitope of a human CD40 that the monoclonal antibody ofthe present invention recognizes can be determined by a known method,such as by examining the binding to overlapping synthetic oligopeptidesobtained from the primary amino acid sequence of human CD40 (e.g., EdHarlow and David Lane (eds.), Antibodies: A Laboratory Manual, 1988 ColdSpring Harbor Laboratory Press; U.S. Pat. No. 4,708,871). A peptidelibrary kit with the phage display process (New England BioLabs) canalso be used for epitope mapping. The present invention also encompassesan antibody or a functional fragment thereof that recognizes a novelepitope of human CD40 that the antibody or the functional fragmentthereof produced by each of the above hybridomas recognizes.(20) The present invention further provides a nucleic acid (RNA or cDNA)encoding at least the variable region of a heavy chain and/or lightchain of an antibody isolated from each of the above hybridomas, avector containing the nucleic acid, and a host cell carrying the nucleicacid.

The present invention will be described in detail. This specificationincludes part or all of the contents as disclosed in the specificationand/or drawings of PCT Application PCT/US01/13672 (filed on Apr. 27,2001), Japanese Patent Application No. 2001-142482 (filed on May 11,2001), Japanese Patent Application No. 2001-310535 (filed on Oct. 5,2001), and U.S. patent application U.S. Ser. No. 10/040,244 (filed onOct. 26, 2001) which are priority documents of the present application.

As described later, we have found that a known monoclonal antibody 5D12(ATCC No. HB-11339) that is antagonistic to CD40 on B cells is notantagonistic to CD40 on DC. We have further found that many monoclonalantibodies show agonistic activity on their own as a result ofcross-linking by anti-immunoglobulin antibodies, even if they areantagonistic antibodies that block the action of CD40L.

1. DEFINITION

The terms used in this specification are defined as follows.

The term “human CD40” in the present invention means a polypeptidehaving an amino acid sequence shown by Clark et al. (E. A. Clark et al.,Proc. Natl. Acad. Sci. USA 83: 4494, 1986) or Stamenkovic et al. (1.Stamenkovic et al., EMBO J. 8: 1403, 1989). Specifically, the human CD40is an antigen polypeptide that is expressed on the surface of a B cell,DC, macrophage, endothelial cell, epithelial cell or tumor cells ofthese cells.

The term “anti-CD40 monoclonal antibody” means any monoclonal antibodyagainst CD40 expressed by a cell, full-length CD40 or partial lengthCD40. A more preferred anti-CD40 monoclonal antibody binds to theextracellular portion of CD40 and provides agonistic or antagonisticaction on the cells expressing CD40.

Furthermore, the term “antibody” in the present invention is derivedfrom a gene (generically called an “antibody gene”) encoding a heavychain variable region, a heavy chain constant region, a light chainvariable region and a light chain constant region composing animmunoglobulin. The antibody of the present invention encompasses anantibody that is of any immunoglobulin class and has any isotype. Theterm “functional fragment” of the antibody in the present invention is apart (a partial fragment) of an antibody as defined above, and means afragment retaining one or more actions of the antibody on an antigen.Specific examples of such functional fragment include F(ab′)₂, Fab′,Fab, Fv, FVs with disulfide bond, single-stranded FV(scFV), and polymersthereof (D. J. King., Applications and Engineering of MonoclonalAntibodies., 1998 T. J. International Ltd).

The term “human antibody” in the present invention means an antibodywhich is the expression product of a human-derived antibody gene.

The term “agonistic” means an action to promote the binding of CD40ligands to CD40 expressed on the surfaces of cells such as B cells,tumor cells or dendritic cells, or an action to provide CD40-expressingcells with one or more effects that are provided by CD40 ligands toCD40-expressing cells. The term “agonistic antibody” means an antibodyhaving such an agonistic action.

The term “antagonistic” means an action to inhibit the binding of CD40ligands to CD40 expressed on the surfaces of cells such as B cells,tumor cells or dendritic cells, or an action to neutralize one or moreeffects that are provided by CD40 ligands to CD40-expressing cells. Theterm “antagonistic antibody” means an antibody having such an action.

The term “dendritic cells (DC)” in the present invention indicates agroup of cells which are also referred to as dendritic leukocytes havinga strong antigen-presenting function. Dendritic cells used herein areinduced by culturing CD34 positive precursor cells contained in, forexample, bone marrow, umbilical cord blood or peripheral blood.Alternatively, the dendritic cells can be obtained by culturing CD14positive monocytes in peripheral blood in the presence of GM-CSF andIL-4.

The term “immature DC” means DC that are CD14 negative, CD1a stronglypositive, CD83, CD86 positive, and MHC class II positive.

The term “mature DC” means DC that are CD14 negative, CD1a positive, andhave become CD83, CD86 and MHC class II strongly positive.

The term “activate DC” in the present invention means a change that DCinduce by responding to the stimulation by CD40. For example, it alsomeans to cause the maturation of immature DC, the high expression ofCD80, CD86 and HLA-Class II, and the enhancement of IL-12 production.Alternatively, when T cells co-exist, it also means to stimulate T cellsto promote their proliferation.

The term “activate B cells and a B cell line” in the present inventionmeans a change that cells induce by responding to the stimulation byCD40. For example, it means to cause DNA synthesis, promote theincorporation of thymidine, and thus to increase the expression amountof CD95.

2. OBTAINMENT OF ANTIBODY

To obtain the antibody of the present invention, it is preferred toimmunize mice using as an antigen a gene recombinant mouse cell lineexpressing a human CD40 or a soluble human CD40 that has been producedand purified with recombinants. Mice to be used for immunization arepreferred to produce human antibodies (Tomizuka. et al., Proc Natl AcadSci USA., 2000 Vol 97: 722). By selecting monoclonal antibodies thatbind to soluble human CD40 that has been produced and purified withrecombinants, antibodies that react also to CD40 expressed on cellsother than B cells may be more easily obtained than by a case whereinclones reacting specifically to B cells are selected. Hybridomas can beproduced by the method of Kohler and Milstein et al. (Nature, 1975 Vol.256: 495) generally used in monoclonal antibody production using thelymphnode cells or splenocytes of immunized mice.

Furthermore, the binding of soluble CD40L to CD40 is analyzed using asurface plasmon resonance system such as BIAcore 2000 (Biacore), andthen antibodies that do not compete with CD40L are selected. Inaddition, antibodies that suppress independently the suppression of thecell growth of B lymphoma are selected. Furthermore, antibody selectionis performed using the condition of whether or not they act on DC as anindicator. This enables the production and selection of antibodies withadvantages of acting on dendritic cells or B cells without competingwith CD40L, and suppressing the proliferation of CD40-expressing cancercells.

The antibody of the present invention is obtained by culturing the thusobtained hybridoma. Further, a gene encoding a human monoclonal antibodyor a variable region thereof is cloned from an antibody-producing cellsuch as a B cell or a hybridoma, the cloned gene is incorporated into anappropriate vector, and then the vector is introduced into a host (e.g.,a mammalian cell line, Escherichia coli, yeast cell, insect cell orplant cell), so that a recombinant antibody produced by generecombination technology can be prepared (P. J. Delves., ANTIBODYPRODUCTION ESSENTIAL TECHNIQUES., 1997 WILEY, P. Shepherd and C. Dean.,Monoclonal Antibodies., 2000 OXFORD UNIVERSITY PRESS; J. W. Goding.,Monoclonal Antibodies: principles and practice., 1993 ACADEMIC PRESS).Moreover, transgenic cattle, goat, sheep or pigs, wherein a targetantibody gene is incorporated into the endogenous gene by transgenicanimal generation techniques are generated. From the milk of thesetransgenic animals, monoclonal antibodies derived from the antibody genecan be obtained in large quantities. When hybridomas are cultured invitro, they are grown, maintained and stored in a way suitable forvarious conditions such as the properties of cell species to becultured, purposes of experiments and studies, and culturing methods.Then, hybridomas can be cultured using any nutrient medium that isinduced and prepared from a known nutrient medium or known basic mediumthat is used for the production of monoclonal antibodies in the culturesupernatant.

3. SCREENING

Screening for agonistic antibodies is performed by analysis using humanB lymphoma, so that antibodies that promote CD95 expression can beselected. Antibodies are further added to a purified DC culturesolution, and then antibodies causing maturation are selected.Alternatively, antibodies showing activity to proliferate T cells in amixed-lymphocyte reaction using immature DC are selected. Furthermore,antibodies are added to mature DC, and then antibodies having action topromote IL-12 production are selected. Furthermore, antibodies havingactivity to suppress the growth of tumor cells expressing CD40 oractivity to induce cell death of the tumor cells are selected.Competition with CD40L can be distinguished from other cases based onwhether or not the antibody inhibits the binding of soluble CD40 withsoluble CD40 ligands using, for example, a surface plasmon resonancesystem (BIOCore). Alternatively, it can also be distinguished from othercases based on whether or not the antibody enhances the action of CD40ligands on a B cell line.

Screening for antagonistic antibodies is performed by analysis usinghuman B lymphoma. Further addition of soluble CD40L having FLAG as a tagin the presence of anti-FLAG antibody enables screening for antibodiesthat inhibit more strongly the binding of soluble CD40L to CD40 on thehuman B lymphoma cell. By the introduction of a gene encoding CD40Linstead of soluble CD40L; it is also possible to use recombinant cellsexpressing many CD40 ligands on the cell surface. Subsequently, humanantibodies are cross-linked with anti-human IgG antibodies, so thatclones that activate B lymphoma by cross-linking are removed.Furthermore, antibodies showing activity to suppress the T cellproliferation in a mixed-lymphocyte reaction using purified and maturedDC, or antibodies having action to suppress IL-12 production when CD40ligands are added to mature DC are selected.

Antibodies that are obtained as described above have at least any of thefollowing properties that are thought to be therapeutically effective.

(1) In the Case of Agonistic Antibody

(a) The antibody acts on dendritic cells to cause IL-12 production inthe presence of LPS (lipopolysaccharide) and IFNγ. The LPS concentrationin this case ranges from 10 pg/ml to 10 μg/ml and the IFNγ concentrationranges from 10⁻⁴ M to 10⁻² M. With an antibody concentration of 1 μg/mlor more, or preferably 0.1 μg/ml or more, the production amount of IL-12is greater than that in a test using a G28-5 antibody as a control, theknown agonistic anti-CD40 antibody. When the antibodies with aconcentration of 0.1 μg/ml or more are added to dendritic cells with aconcentration of 1×10⁶ cells/ml, 100 pg/ml or more IL-12 is produced, orwhen the same with a concentration of 1 μg/ml or more are added, 1,000pg/ml or more, or preferably, 10,000 pg/ml or more IL-12 is produced(see Examples 9 and 13).

(b) The antibody has action of binding to dendritic cells and thus tocause the maturation of the dendritic cells. Moreover, when theantibodies with a concentration of 20 μg/ml or less, preferably 0.1 to15 μg/ml; further preferably 5 to 15 μg/ml were cultured with dendriticcells, the activity to cause maturation is higher than that of the G28-5antibody (see Example 9).

(c) The antibody has activity to promote CD95 expression of anestablished B cell line, which is greater than that of the G28-5antibody. In this case, with an antibody concentration of 10 μg/ml ormore, preferably 1 μg/ml or more, further preferably 0.1 μg/ml or more,still further preferably 0.01 μg/ml or more, and most preferably 0.001μg/ml or more, the activity to promote CD95 expression is higher thanthat of the G28-5 antibody that is used as a control in a test. Theratios of the activity of the G28-5 antibody, which was used in a testas a control, to promote CD95 expression to the same of the antibodywith concentrations of 10 μg/ml, 1 μg/ml, 0.1 μg/ml and 0.01 μg/ml areas shown below (Table 1).

TABLE 1 Antibody concentration Ratio   10 μg/ml Approximately 2-fold,preferably approximately 3-fold, more preferably 4.5-fold, and furtherpreferably 6-fold   1 μg/ml Approximately 2-fold, preferablyapproximately 5-fold, more preferably approximately 6-fold, and furthermore preferably 7-fold  0.1 μg/ml 2-fold, preferably 6-fold, morepreferably approximately 7-fold 0.01 μg/ml 2-fold, preferably 4-fold,more preferably 5-fold, further preferably approximately 6-fold

The promoted expression of CD95 means that the antibody activates theestablished B cell line. Here, examples of the established B cell lineinclude Ramos cells and HS-Sulton cells. In addition, Ramos cells are ofBurkitt's lymphoma, which are model cells of human centroblastic Bcells. HS-Sulton cells are of Burkitt's lymphoma (see Examples 6 and12).

(d) The antibody has activity to suppress the DNA synthesis, thymidineincorporation, and proliferation of the established B cell line (Ramoscells or HS-Sulton cells), which is higher than that of G28-5 antibody.The antibody concentration in this case is at least 0.05 μg/ml, orpreferably 0.1 to 15 μg/ml (see Example 8).

(e) The antibody induces cell death of the established B cell line (seeExample 16).

(f) The antibody does not inhibit the binding of CD40 ligands to CD40.The term “does not inhibit” means that CD40L can bind to CD40 to thesame degree as that when the antibody is absent, even when the antibodypreviously binds to CD40 (that is, in the presence of the antibody).Either one of or both CD40 ligands and CD40 may be a type of a proteinthat is expressed on the membrane or a soluble protein (see Example 11).

Antibodies having the above properties are produced, for example, by ahybridoma KM302-1 (FERM BP-7578) and a hybridoma KM341-1-19 (FERMBP-7759).

The nucleotide sequences and amino acid sequences of the heavy chain (Hchain) and light chain (L chain) variable regions of a monoclonalantibody produced by the hybridoma KM341-1-19 were determined (Example17). The present invention provides DNA encoding at least the heavychain variable region, or the full-length heavy chain, and DNA encodingthe light chain variable region of the monoclonal antibody produced bythe hybridoma KM341-1-19. The DNAs also include other DNAs encoding thesame amino acid sequences due to codon degeneration in addition to thosedescribed in Example 17. Moreover, the present invention providesmonoclonal antibodies or functional fragments thereof as specified bythe amino acid sequences of at least the heavy chain variable regions orthe amino acid sequences of the full-length heavy chains, and the aminoacid sequences of the light chain variable regions, as disclosed inExample 17.

(2) In the Case of Antagonistic Antibody

(g) The antibody neutralizes the action of ligands for CD40. Here, theterm “the action of ligands” means both the action of ligands expressedon T cells or other cells, and the action of free ligands for CD40 (seeExamples 7 and 14).

(h) The antibody neutralizes one or more effects that ligands for CD40on the established B cell line have on CD40-expressing cells, and do notshow agonistic action to CD40 on the above established B cell line bycross-linking by anti-immunoglobulin antibodies. This action is weakerthan that of 5D12. The “effects that ligands have on CD40-expressingcells” mean the activation of the CD40-expressing cells. Specifically inB cells, the effect means the activation of thymidine incorporation andB cell proliferation, and the activation of the enhanced expression ofCD95 in the established B cell line. Furthermore, in DC, the effectmeans the activation of DC maturation, the activation of the enhancedexpression of CD86 and HLA-DR, the activation of thymidine incorporationby the co-existing T cells, the promotion of the proliferation, theactivation of IL-12 and IL-10 production, and the like. Cross-linking byanti-immunoglobulin antibodies is performed by causing the presence of0.1 μg/ml or more of anti-immunoglobulin antibodies in a culturesolution (see Example 7).

(i) The antibody alleviates or neutralizes the activity of cross-linkedCD40L or CD40L expressed by cells to enhance the expression of CD95 inthe established B cell line. The antibody also alleviates or neutralizesthe activity of CD40L, the action of which is enhanced by cross-linkingby antibodies and the like against tags. The binding of ligands(including both free ligands and ligands expressed by specific cells)for CD40 to CD40-expressing cells causes intracellular signaltransduction, and finally causes the cells to express CD95 (Fas) on thecell surfaces. Accordingly, the antagonistic antibody of the presentinvention inhibits the above signal transduction by binding to CD40,thereby neutralizing the expression of CD95. The antibody concentrationin this case is 1 μg/ml or more, or preferably 0.1 μg/ml or more (seeExamples 7 and 14).

(j) The antibody is antagonistic to CD40 on DC. Specifically, theantibody alleviates or neutralizes the activity of CD40L to activate DC.When DC are stimulated by ligands on T cells co-existing with the DC, Tcells are activated, so that thymidine incorporation and the like arepromoted. In the mixed-lymphocyte reaction, wherein DC and T cells thatare both derived from different individuals are allowed to co-exist, DCinteract with T cells, thereby causing T-cell activation. Theantagonistic antibody of the present invention inhibits the aboveinteraction by binding to CD40, resulting in suppressed incorporation ofthymidine. The antibody concentration in this case is at least 0.001μg/ml, or preferably 0.1 to 10 μg/ml (see Example 10).

The above antagonistic antibody is produced by, for example, hybridomasKM281-1-10 (FERM BP-7579) and KM281-2-10⁻¹-2 (FERM BP-7580) (May 9,2001, the International Patent Organism Depositary (IPOD) at theNational Institute of Advanced Industrial Science and Technology(Central 6, 1-1-1, Higashi, Tsukuba, Ibaraki) and 4D11 (FERM BP-7758).

(3) The antibody of the present invention can be altered to an antibodyof a different subclass (for example, see EP314161 publication), bymodification by genetic engineering techniques known by a person skilledin the art, specifically by substituting a region that defines thesubclass of an antibody heavy chain with a region that defines anothersubclass. A heavy chain variable region and the constant region ofanother subclass can be directly linked. For example, an alteration ofthe subclass of the antibody of the present invention to IgG2 or IgG4makes it possible to lower the binding degree of the antibody to a Fcreceptor. Specifically, Nhe I site (GCTAGC) is introduced into a humanantibody heavy chain, EU index 118 (Ala), 119 (Ser) site according toKabat et al (Sequence of Proteins of Immunological Interest, 5^(th) Ed.Public Health Service, National Institute of Health, Bethesda, Md.(1991)). By digestion using the restriction enzyme, switching to anothersubclass, IgG, can be performed without altering the amino acid.Moreover, artificial alteration of the amino acid sequence of a constantregion, or the binding of a constant region sequence having such analtered sequence with the variable region of the antibody of the presentinvention can lower the binding degree to a Fc receptor (Lund J., etal., J. Immunol. 1991 vol 147: 2657-2662), or can also increase ordecrease CDC activity (Tao M., et al., J. Exp. Med. 1991 vol 1025-1028,Idusogie E E., et al., J. Immunol. 2001 vol 166: 2571-5). Furthermore,to avoid the action of ADCC, CDC or the like, only IgG2 or IgG4 subclassantibodies can be previously selected. In addition, the binding of aradionuclide, bacterial toxin, chemotherapeutant, prodrug or the likewith the antibody of the present invention can further enhance thetherapeutic effect against disease such as cancer.

4. Pharmaceutical Composition

A pharmaceutical composition containing a pharmaceutical preparationthat is the purified antibody of the present invention is alsoencompassed by the scope of the present invention. Such a pharmaceuticalcomposition preferably contains a physiologically acceptable diluent orcarrier in addition to the antibody, or may be a mixture with otherantibodies or other drugs, such as antibiotics. Examples of theappropriate carrier include, but are not limited to, a physiologicalsaline solution, a phosphate buffered saline solution, a phosphatebuffered saline glucose solution and a buffered physiological saline.Alternatively, the antibody is freeze-dried, and then used whennecessary by adding the above buffered aqueous solution forreconstruction. Examples of the route of administration include an oralroute and a parenteral route including intravenous, intramuscular,hypodermic and intraperitoneal injections or drug delivery.

In this case, the effective dose to be administered as a combination ofthe effective dose of the antibody of the present invention, anappropriate diluent, and a pharmacologically acceptable carrier rangesfrom 0.1 mg to 100 mg per kg of body weight per administration.Administration is performed at intervals of 2 days to 8 weeks.

When a pharmaceutical composition containing the antibody of the presentinvention is used, and particularly, when the agonistic antibody isused, the composition is used as an immunopotentiating drug (anti-viralagent and anti-infective drug), anti-tumor agent or anti-autoimmunedisease agent. Multiple examples of these diseases may occur together.Alternatively, the antibody can also be used as an adjuvant incombination with a vaccine such as a cancer-specific peptide. When thecomposition contains the antagonistic antibody, it is useful as animmunosuppressive agent (prophylactic or therapeutic agent againstimmunological rejection or GVHD upon transplantation of islets ofLangerhans, kidneys or the like) upon organ transplantation, or ananti-autoimmune disease agent (e.g., against rheumatism, or as atherapeutic agent against arterial sclerosis, disseminated sclerosis,systemic erythematodes, idiopathic thrombocythemia or Crohn's disease),therapeutic agent against allergies such as asthma, or therapeutic agentagainst blood coagulation factor VIII-inhibiting syndrome. Multipleexamples of these diseases may occur together.

When the anti-CD40 antibody is used as a therapeutic means against adisease in which CD40 is involved, it can be expected that antibodiesproviding a better therapeutic effect can be obtained by selecting theantibodies using the function of DC as an indicator.

In the case of the agonistic antibody, it can be expected thatantibodies having strong immunopotentiation action can be obtained byselecting antibodies that can activate DC more effectively. Furthermore,by using the promotion of IL-12 production by mature DC as an indicator,antibodies having strong CTL-inducing action can be obtained. By the CTLinduction, antibodies that are highly effective for removing cellsinfected with viruses or tumor cells can be obtained. Moreover, sincesynergistic effects can be expected, preferred antibodies bind to CD40without inhibiting the binding of CD40 ligands to CD40. When cancertreatment is considered, if antibodies that directly induce cell deathof CD40-expressing cancer cells or suppress their proliferation, andeffectively activate DC are present, synergistic effects are expectedtherefrom, and such antibodies can be a therapeutic agent that can beused against tumors that do not express CD40. These antibodies areconsidered to be useful as a therapeutic agents against viral diseasesor anti-tumor agents.

In the meantime, antibodies that specifically bind to CD40 and suppressthe binding of CD40L without activating CD40 are also expected to beable to suppress not only the action of ligands for B cells, but alsothe action on DC. However, antibodies have been so far obtained using asan indicator their effect on B cells. Thus, it is highly significant toobtain antibodies that have strong suppressive action also on dendriticcells and to develop them as a pharmaceutical product. Further, it is aconcern that the anti-CD40 antibody can have a totally opposite actionby cross-linking as described above. Thus, antibodies that do notactivate CD40 even by cross-linking are required. It is also a concernthat monoclonal antibodies derived from a non-human mammal such as amouse, chimeric antibodies consisting of the variable region of a mousemonoclonal antibody and a constant region of a human immunoglobulin andhumanized antibodies resulting from CDR grafting, which have been so farreported as antibodies against human CD40, have antigenicity. Therefore,a human antibody is desirable as an antibody to inhibit the binding withCD40 ligands.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows that KM302-1 antibodies promoted CD95 expression.

FIG. 2A shows that the antagonistic antibodies neutralized the action ofCD40 ligands on Ramos cells.

FIG. 2B shows that the antagonistic antibodies neutralized the action ofCD40 ligands on Ramos cells.

FIG. 3 shows that KM281-1-10 antibodies neutralized the action of CD40ligands on Ramos cells.

FIG. 4 shows that cross-linked KM281-1-10 antibodies did not promoteCD95 expression.

FIG. 5 shows that cross-linked 5D12 antibodies promoted CD95 expression.

FIG. 6 shows the proliferation suppressive effect of KM302-1 antibodieson tumor cells.

FIG. 7 shows that KM302-1 antibodies promoted the maturation of DC.

FIG. 8 shows that KM302-1 antibodies promoted the IL-12 production ofDC.

FIG. 9 shows that KM281-1-10 antibodies neutralized the action of CD40ligands on DC.

FIG. 10 shows that KM281-1-10 antibodies neutralized the action of CD40ligands on DC.

FIG. 11 shows that KM302-1 antibodies activated immature DC-MLR.

FIG. 12 shows that KM341-1-19 antibodies and the like promoted CD95expression of Ramos cells.

FIG. 13 shows that KM341-1-19 antibodies promoted IL-12 production ofmature DC.

FIG. 14 shows that KM341-1-19 antibodies promoted IL-10 production ofmature DC.

FIG. 15 shows that 4D11 antibodies and the like neutralized the actionof CD 40 ligands on Ramos cells.

FIG. 16 shows that KM302-1 antibodies showed anti-tumor effect on thehuman tumor cell-transplanted mouse model.

FIG. 17 shows that KM341-1-19 antibodies showed a proliferationsuppressive effect against tumor cells.

FIG. 18 shows that F4-465, 4D11 and KM28′-1-10 suppressedantigen-specific IgG production.

FIG. 19 shows that F4-465, 4D11 and KM281-1-10 suppressedantigen-specific IgM production.

FIG. 20 shows that F4-465 suppressed the proliferation of tonsillar Bcells.

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention will be further described in detail by referringto the examples. However, the technical scope of the invention is notlimited by these examples.

Example 1 Preparation of Antigen (1) Cell

EL-4 cells are of a mouse-derived established T cell line, and can beeasily obtained (ATCC No.: TIB-39). Ramos B cells (ATCC No.: CRL-1596)and mouse anti-CD40 antibody-producing hybridoma G28-5 (HB-9110) and5D12 (HB-11339) were purchased from ATCC.

(2) Expression and Purification of Antigen

Extracellular regions were amplified by PCR using human CD40 cDNA(Genbank Accession Number: NM_(—)001250) as a template and the followingprimers under conditions of 20 cycles of 95° C. for 5 seconds, 55° C.for 30 seconds and 72° C. for 30 seconds.

Primer 1: (SEQ ID NO: 1) 5′-CCCAGATCTGTCCATCCAGAACCACCCACTGCATGCAGAG-3′Primer 2: (SEQ ID NO: 2) 5′-ACAAGATCTGGGCTCTACGTATCTCAGCCGATCCTGGGGAC-3′

The amplified cDNA was inserted following the melittin signal sequenceand before the human IgG1-derived FC or mouse IgG2a-derived FC region ofa pFastBac vector (Gibco BRL). To produce CD40, recombinantbaculoviruses were prepared according to the instruction. Th5 cells wereinfected with the recombinant viruses, and then cultured for 4 days. Thesupernatant was treated with a 0.22 nm filter, Protein G sepharose(Amersham Pharmacia) was added thereto, and then the mixture was gentlyshaken at 4° C. After one night, sepharose was transferred to a columnand then washed with a 20× volume of PBS. A human CD40 FC protein waseluted with a 20 mM glycine buffer (pH 3.0). The vector to express CD40on cell surfaces was obtained from Randolph J. Noelle (Inui, S et al.,EJI, 20, 1747-1753, 1990). The full-length cDNA was cleaved with the XbaI enzyme, and then inserted into pCDNA3 (INVITROGEN). The vector wasintroduced into EL-4 cells, and then the cells were cultured in thepresence of 0.5 mg/ml G418 (Gibco BRL), thereby obtaining a stableexpression strain. The expression of CD40 was confirmed by FACS analysisusing FITC-conjugated anti-human CD40 antibodies (Pharmingen).

Example 2 Generation of Mice for Immunization

The mice used for immunization had a genetic background whereby theywere homozygotes for both disrupted endogenous Ig heavy chain and Klight chain, and the mice harbored at the same time chromosome 14fragment (SC20) containing human Ig heavy chain gene locus, and humanIgκ chain transgene (KCo5). These mice were generated by crossing miceof a line A having a human Ig heavy chain gene locus with mice of a lineB having a human Igκ chain transgene. The mice of line A are homozygousfor both disrupted endogenous Ig heavy chain and K light chain, andharbor chromosome 14 fragment (SC20), which is transmittable to progeny,as is described, for example, in the report of Tomizuka et al.(Tomizuka. et al., Proc Natl Acad Sci USA., 2000 Vol 97: 722). The miceof the line A were immunized, so that the following hybridomas F2-103and F5-77 were obtained. Furthermore, the mice of line B (transgenicmice) are homozygotes for both disrupted endogenous Ig heavy chain and κlight chain, and harbor a human Igκ chain transgene (KCo5), asdescribed, for example, in the report of Fishwild et al. (Nat.Biotechnol., 1996 Vol 14:845).

Individuals obtained by crossing male mice of the line A with femalemice of the line B, or female mice of the line A with male mice of theline B, and having human Ig heavy chain and κ light chain detectedsimultaneously in the sera (Ishida & Lonberg, IBC's 11th AntibodyEngineering, Abstract 2000) were used for the following immunizationexperiment. In addition, the above human antibody-producing mice areavailable from Kirin Brewery Co., Ltd via contract. By immunizing theabove mice, the following hybridomas KM302-1, KM341-1-19, KM643-4-11,2053, 2105, 3821, 3822, 285, 110, 115, KM281-1-10, KM281-2-10-1-2,KM283-5, KM292-1-24, KM225-2-56, KM341-6-9, 4D11, 5H10, 11E1, 5G3, 3811,3411 and 3417 were obtained. Moreover, chimeric mice (Kuroiwa et al.,Nat. Biotechnol., 2000 vol 18:1086) harboring human antibody Lambdachain reported by Kuroiwa et al. were also used for the followingimmunization experiment. A hybridoma F4-465 was obtained from the mouse.

Example 3 Preparation of Human Monoclonal Antibody Against Human CD40

Monoclonal antibodies in this example were prepared according to ageneral method described in the Introduction of Experimental Proceduresfor Monoclonal Antibodies (written by Tamie ANDO et al., KODANSHA,1991). The human CD40 used as an immunogen herein were the human CD40human FC and CD40-expressing EL-4 cells prepared in Example 1. Animalsused herein for immunization were human antibody-producing mice thatproduce the human immunoglobulin prepared in Example 2.

The human antibody-producing mice were immunized with 2 to 100μg/immunization of CD40: hFc per mouse. Excluding the firstimmunization, an antigen solution was mixed with an equivalent volume ofFreund's incomplete adjuvant (Sigma), and then injected subcutaneouslyinto several separate positions. Immunization was performed 3 to 4 timesapproximately every 10 days to 3 weeks. For the first immunization,Freund's incomplete adjuvant (Sigma) was used. Blood was collected fromthe mouse tail, and then human antibody γ and κ against CD40 in theserum were measured using ELISA. 3 to 4 days before excision of thespleen, final immunization was performed by injecting 20 μg of CD40: Fcdissolved in PBS via the caudal vein.

The human antibody-producing mice were immunized with humanCD40-expressing mouse EL-4 cells. EL-4 cells (10⁸ cells/ml) weresuspended in PBS, and then gently mixed with an equivalent volume ofRIBI adjuvant previously emulsified with PBS. Immunization was performedwith the cells 3 to 5 times approximately every 10 days to 3 weeks. Whenthe adjuvant was not used, the cells were irradiated with X-rays with8000 rad for use.

The spleen was surgically obtained from the immunized mice. Thecollected splenocytes were mixed with mouse myeloma SP2/0 (ATCC No.:CRL1581) at a ratio of 5 to 1. The cells were fused using polyethyleneglycol 1500 (Boehringer Mannheim) as an agent for cell fusion, therebypreparing a large number of hybridomas. The selection of hybridomas wasperformed by culturing in HAT-containing DMEM media (Gibco BRL)supplemented with 10% fetal calf serum (FCS), hypoxanthine (H),aminopterin (A) and thymidine (T). Furthermore, single clones wereobtained by the limiting dilution method using HT-containing DMEM media.Culturing was performed in a 96-well microtiter plate (BecktonDickinson). Screening for hybridma clones producing anti-human CD40human monoclonal antibodies was performed by measurement usingenzyme-linked immuno adsorbent assay (ELISA) and fluorescence activatedcell sorter (FACS), as described later in Example 4.

Screening for the human monoclonal antibody-producing hybridoma by ELISAwas performed by 3 types of ELISA and FACS analyses as described below.Thus, a large number of hybridomas producing human monoclonal antibodiesthat had human immunoglobulin γ chain (hIgγ) and human immunoglobulinlight chain K, and had reactivity specific to human CD40 were obtained.In any of the following examples including this example, and tables andfigures showing the test results of the examples, each hybridoma cloneproducing the human anti-human CD40 monoclonal antibody of the presentinvention was denoted using symbols. A clone represented by the symbolsfollowed by “antibody” means an antibody that is produced by each of thehybridomas, or a recombinant antibody that is produced by a host cellcarrying an antibody gene (full-length or a variable region) isolatedfrom the hybridoma. In addition, within a contextually clear range, thename of a hybridoma clone may express the name of an antibody.

The following hybridoma clones represent single clones.

Agonistic Antibody: KM302-1, KM341-1-19, KM643-4-11, 2053, 2105, 3821,3822, 285, 110, 115, F1-102, F2-103, F5-77 and F5-157 AntagonisticAntibody: KM281-1-10, KM281-2-10⁻¹-2, KM283-5, KM292-1-24, KM225-2-56,KM341-6-9, 4D11, 5H10, 11E1, 5G3, 3811, 3411, 3417 and F4-465

3 hybridoma clones KM 302-1, KM 281-1-10 and KM 281-2-10⁻¹-2 among themwere deposited on May 9, 2001, clones KM341-1-19 and 4D11 were depositedon Sep. 27, 2001, and clone 2105 was deposited on Apr. 17, 2002, withthe International Patent Organism Depositary at the National Instituteof Advanced Industrial Science and Technology (Central 6, 1-1-1,Higashi, Tsukuba, Ibaraki, Japan) under the Budapest Treaty. Plasmidshaving the heavy chain and light chain variable regions of F2-103, F5-77and F5-157, were deposited on Apr. 19, 2001, and hybridoma clones F1-102and F4-465 were deposited on Apr. 24, 2001, with ATCC (American TypeCulture Collection, University Blvd, Manassas, Va., U.S.A.) under theBudapest Treaty (Table 2).

TABLE 2 Name Accession No. KM302-1 FERM BP-7578 KM281-1-10 FERM BP-7579KM281-2-10-1-2 FERM BP-7580 KM341-1-19 FERM BP-7759 4D11 FERM BP-77582105 FERM BP-8024 F1-102 ATCC PTA-3337 F4-465 ATCC PTA-3338 F2-103 heavychain ATCC PTA-3302 (F2-103-H) F2-103 light chain ATCC PTA-3303(F2-103-L) F5-77 heavy chain (F5-77-H) ATCC PTA-3304 F5-77 light chain(F5-77-L) ATCC PTA-3305 F5-157 heavy chain ATCC PTA-3306 (F5-157-H)F5-157 light chain ATCC PTA-3307 (F5-157-L)

Example 4 Screening for Hybridoma

Detection of monoclonal antibody having human immunoglobulin γ chain

The human CD40 mouse FC (1 μg/ml) prepared in Example 1 was added at 50μl/well to each well of a 96-well microplate for ELISA (Maxisorp, Nunc)and incubated at 4° C. for the human CD40 mouse FC to be adsorbed to themicroplate. Next, the supernatant was discarded, and then a blockingreagent (Block Ace, DAINIPPON PHARMACEUTICAL) was added to each well,followed by incubation at room temperature for blocking. The culturesupernatant (50 μl) of each hybridoma was added to each well forreaction, and then each well was washed with a 0.1% Tween20-containingphosphate buffer (PBS-T). Goat anti-human IgG (γ) antibody (Sigma,A0170) labeled with peroxydase was then diluted 5,000-fold with 1%FBS-containing PBS-T. The solution was added (50 μl/well) to each well,and then incubation was performed. The microplate was washed 3 timeswith PBS-T, and then a chromogenic substrate solution (TMB, 50 μl/well,SUMITOMO BAKELITE) was added to each well, followed by incubation atroom temperature for 30 minutes. A stop solution was added (50 μl/well)to each well to stop reaction. Absorbance at a wavelength of 450 nm wasmeasured with a microplate reader. The culture supernatant of positivewells was analyzed by FACS, an then the wells wherein Ramos cells werestained were selected. The cells in the wells were cloned by thelimiting dilution method, and then the cells of 1 clone were obtainedper well. hκ-positive status was confirmed by ELISA using the human CD40mouse FC. As a result, anti-human CD40 antibodies of 173 clones wereobtained from 20 mice. Some of these antibodies were shown in Table 3(agonistic antibodies) and Table 4 (antagonistic antibodies). Among theagonistic antibodies, at least KM341-1-19 and 2105 did not significantlycompete with ligands in a competitive test using CD40L-expressing cells,CD40-expressing cells and the antibodies.

TABLE 3 Agonistic antibody Hybridoma Antigen Subclass DC Tumor cellKM302-1 CD40 mouse FC IgG4 activated suppressed proliferation KM341-1-19human IgG2 activated suppressed CD40-expressing proliferation EL-4KM643-4-11 CD40 mouse FC IgG1 not not implemented implemented 2053 CD40mouse FC IgG2 not not implemented implemented 2105 CD40 mouse FC IgG2not not implemented implemented 3821 human IgG3 not not CD40-expressingimplemented implemented EL-4 3822 human IgG3 not not CD40-expressingimplemented implemented EL-4  285 CD40 mouse FC IgG1 not not implementedimplemented  110 CD40 mouse FC IgG4 not not implemented implemented  115CD40 mouse FC IgG4 not not implemented implemented F2-103 CD40 mouse FCIgG1 not not implemented implemented F5-77 CD40 mouse FC IgG1 not notimplemented implemented

TABLE 4 Antagonistic antibody Effect of cross- Hybridoma AntigenSubclass linking DC-MLR KM281-1-10 CD40 mouse FC IgG1 low suppressedKM281-2- CD40 mouse FC IgG1 low not 10-1-2 implemented KM283-5 CD40mouse FC IgG4 significant not suppressed KM225-2-56 CD40 mouse FC IgG4significant not implemented KM292-1-24 CD40 mouse FC IgG2 significantnot implemented KM341-6-9 human IgG1 significant not CD4-expressingimplemented EL-4 4D11 CD40 mouse FC IgG1 low not implemented 5H10 CD40mouse FC IgG1 low not implemented 11E1 CD40 mouse FC IgG1 low notimplemented 5G3 CD40 mouse FC IgG2 significant not implemented 3811human IgG1 significant not CD40-expressing implemented EL-4 3411 humanIgG2 significant not CD40-expressing implemented EL-4 3417 human IgG2significant not CD40-expressing implemented EL-4 F4-465 human IgG1 notnot CD40-expressing implemented implemented EL-4

Monoclonal antibodies having human immunoglobulin light chain κ (Igκ)were detected in a manner similar to the above described ELISA methodfor human immunoglobulin γ chain except that goat anti-human Igκantibodies (diluted 1,000-fold, 50 μl/well, Southern Biotechnology)labeled with peroxydase were used.

The subclass of each monoclonal antibody was identified in a mannersimilar to the above ELISA method for human immunoglobulin γ chain,except that a sheep anti-human IgG1 antibody, sheep anti-human IgG2antibody, sheep anti-human IgG3 antibody or sheep anti-human IgG4antibody (each diluted 2,000-fold, 50 μl/well, The Binding Site) labeledwith peroxydase, was used.

Reaction Test of Each Monoclonal Antibody Against Human CD40-ExpressingCells

The reactivity of each monoclonal antibody against a Ramos cell linereported to express CD40 was studied by FACS analysis.

The Ramos cell line was suspended at a concentration of 2×10⁶/ml in astaining buffer (SB) of 0.1% NaN₃ and 2% FCS-containing PBS. The cellsuspension (100 μl/well) was apportioned to a 96-well round bottom plate(Beckton Dickinson). The culture supernatant (50 μl) of each hybridomawas added, and then incubation was performed at ice temperature for 30minutes. Human IgG1 antibodies against human serum albumin were used asa negative control, and prepared at a concentration of 2 μg/ml with ahybridoma culture medium. 50 μl of the solution was added, and thenincubation was performed at ice temperature for 15 minutes. Afterwashing with SB, 50 μl of R-PE fluorescence-labeled anti-human antibody(Southern Biotechnology) diluted 250-fold was added, and then incubationwas performed at ice temperature for 15 minutes. After washing twicewith SB, the product was suspended in 300 to 500 μl of a FACS buffer,and then the fluorescence intensity of each cell was measured by FACS(FACSort and FACScan, Beckton Dickinson). As a result, antibodies havingbinding activity for the Ramos cell line were selected.

Example 5 Preparation of Each Antibody

The culture supernatant containing monoclonal antibodies was prepared bythe following method.

A G28-5 antibody-producing hybridoma was obtained from ATCC (ATCC No.HB-9110). Anti-CD40 antibody-producing hybridomas were acclimatized ineRDF media (Kyokutoseiyaku) containing bovine insulin (5 μg/ml, GibcoBRL), human transferrin (5 μg/ml, Gibco BRL), ethanolamine (0.01 mM,Sigma) and sodium selenite (2.5×10⁻⁵ nM, Sigma). The hybridomas werecultured in a spinner flask. When the viable cell rate of the hybridomasreached 90%, the culture supernatant was collected. The collectedsupernatant was applied to a 10 μm and 0.2 μm filters (German Science)so as to eliminate miscellaneous debris such as hybridomas.

Anti-CD40 antibodies were purified from the above culture supernatant bythe following method. The culture supernatant containing the anti-CD40antibodies was subjected to affinity purification using a Hyper DProtein A column (NGK INSULATORS, LTD) or a Protein G column (forpurifying mouse IgG1, Amersham Pharmacia Biotech) according to theattached instruction using PBS (−) as an adsorption buffer and 0.1 Msodium citrate buffer (pH 3) as an elution buffer. 1 M Tris-HCl (pH 8.0)or Na₂HPO₄ solution was added to adjust the elution fraction to have apH of around 7.2. The prepared antibody solution was substituted withPBS (−) using a dialysis membrane (10000 cut, Spectrum Laboratories) orSP column (Amersham Pharmacia Biotech), and then sterilization byfiltration was performed using a membrane filter MILLEX-GV (MILLIPORE)with a pore size of 0.22 μm. The concentration of the purified antibodywas found by measuring absorbance at 280 nm and then calculating with 1mg/ml at 1.45 OD.

Example 6 Promotion of CD95 Expression in Ramos Cells by Anti-CD40Agonistic Antibody

A 5.0×10⁵ cells/ml Ramos cell suspension was inoculated at 100 μl/well(5×10⁴ cells per well) to a 96-well plate. The hybridoma culturesupernatant or the purified antibody was diluted to 20 μg/ml with amedium, and then the solution was added at a concentration of 100μl/well to a 96-well plate. After overnight culture, the cells werecollected and then analyzed by FACSCan or FACSsort (Beckton Dickinson)using R-PE-labeled anti-CD95 antibodies (Pharmingen N.J.). FIG. 1 showsthe result. The horizontal axes in FIG. 1 indicate the expressionintensity of CD95. Addition of antibodies is indicated with a thickline, and non addition of antibodies is indicated with a thin line. Itwas shown that the KM302-1 antibodies promoted CD95 expression betterthan G28-5 antibodies, which were the known antibodies. That is, theKM302-1 antibody was shown to be more effectively agonistic.

Example 7 Suppression of CD95 Expression in Ramos Cell by Anti-CD40Antagonistic Antibody

A 1.0×10⁶ cells/ml Ramos cell suspension was inoculated at 50 μl/well toa 96-well plate. The hybridoma culture supernatant or the purifiedantibody was adjusted at 2 μg/ml with a medium, and then added at 100μl/well to a 96-well plate. Soluble CD40 ligands (4 μg/ml, ALEXISCORPORATION) and anti-FLAG antibodies (4 μg/ml, M2, Sigma) were added tomedia, and then the media were added at 50 μl/well to the 96-well plate.After overnight culture, the cells were collected and then analyzed byFACS using R-PE-labeled anti-CD95 antibodies (Pharmingen N.J.). FIGS. 2Aand 2B, and 3 show the results. The horizontal axes in the figuresindicate the expression intensity of CD95. CD95 expression wassuppressed to the same degree as that of a negative control by theantibodies produced by each of the following hybridomas: KM281-1-10,KM281-2-10⁻¹-2, KM283-5, KM292-1-24 and KM225-2-56.

In FIG. 3, KM281-1-10 antibodies (lower panel) suppressed CD95expression more effectively than that the 5D12 antibodies (centralpanel), the known antibody only slightly suppressed CD95 expression.Specifically, the KM281-1-10 antibody was shown to be more effectivelyantagonistic. Thus, the human monoclonal antibody was shown to be anantagonistic antibody.

Effect of Cross-Linking by Anti-Immunoglobulin Antibody

A 1.0×10⁶ cells/ml Ramos cell suspension was inoculated at 50 μl/well toa 96-well plate. The hybridoma culture supernatant or the purifiedantibody was adjusted to 2 μg/ml with a medium, and then added at 100μl/well to a 96-well plate. Anti-human IgG antibodies (Sigma, 13382) oranti-mouse IgG antibodies (Biosource, AMI3401) were added at 4 μg/ml tomedia, and then the media were added at 50 μl/well to a 96-well plate.After overnight culture, the cells were collected, and then analyzed byFACS using R-PE-labeled anti-CD95 antibodies (Pharmingen N.J.). FIGS. 4and 5 show the results. The horizontal axes in the figures indicate theexpression intensity of CD95. CD95 expression was suppressed by theantibodies produced by each of the hybridomas KM281-1-10 andKM281-2-10⁻¹-2. Conversely, CD95 expression was enhanced by theantibodies produced by each of the following hybridomas, 5D12, KM283-5,KM292-1-24 and KM225-2-56.

Example 8 Proliferation Suppression in Ramos Cells by Anti-CD40Agonistic Antibody

A 1.0×10⁵ cells/ml Ramos and HS-Sulton cell suspension was inoculated at100 μl/well to a 96-well plate. A mixture of equivalent amount of thepurified antibodies or soluble CD40 ligands, and anti-FLAG antibodies(M2) was added to media. After 2 days of culturing, 10 μl of 100 μCi/ml³H-Thymidine (Amersham Pharmacia) was added. After 18 hours, the cultureproduct was harvested in a Printed Filtermat A (Wallac) using a Macro 96Harvester (SKATRON), dried, and then immersed well in Betap; Scint(Wallac). After packaging, activity was measured using a 1205 BETAPLATEliquid scintillation counter. FIG. 6 shows the results. In the figure,the longitudinal axes indicate the amount of ³H thymidine incorporatedby cells, and the horizontal axes indicate the concentration of theantibody or CD40L in the culture solution. When the KM302-1 antibodieswere added to Ramos cells and HS-Sulton cells, the amount of thymidineincorporated was lower than the conventional G28-5 antibodies and CD40L.Thus, it was shown that the KM302-1 antibody is an agonistic antibodythat can effectively suppress the proliferation of tumor cells.

Example 9 Activation Of Dendritic Cell by CD40 Agonistic Antibody

(1) Materials and methods

Recombinant human IL-4 was purchased from Genzyme techne. Anti-humanCD14 MACS beads were purchased from Miltenyi Biotech GmbH. Lymphoprepwas purchased from Nycomed Pharma AS. The medium used for culturing wasRPMI1640 (Gibco BRL) supplemented with 10% heat inactivated FCS (CellCulture Technologies), 10 mM HEPES (Sigma), 55 μM 2-mercaptoethanol(Gibco BRL) and streptomycin sulfate (MEIJI SEIKA KAISHA, LTD.), when DCwere induced. The cells in a staining process were washed with PBS(Sigma) supplemented with 2% FCS (Cell Culture Technologies) and 0.02%Azaid. When the cells were frozen, Cell banker (Nippon Zenyaku Kogyo)was used.

(2) Induction of Monocyte-Derived DC

Mononuclear cells were prepared (PBMC) from peripheral blood by densitygradient centrifugation using Lymphoprep. The cells were subjected topositive selection using anti-human CD14 MACS beads, so as to separatethe cells into a CD14 positive fraction and negative fraction.Recombinant human GM-CSF (50 ng/ml) and recombinant human IL-4 (100ng/ml) were added to the positive fraction, followed by culturing inRPMI1640 media supplemented with 10% FCS in a 6-well plate. At the startof culturing, the cells were cultured at a concentration of 1×10⁶/ml (3ml per well). During culturing, the media were exchanged once every 2days. Medium exchange was performed by sampling 10% of the culturesolution in a centrifugation tube, centrifuging the solution, removingthe supernatant, suspending with a new culture solution (containingcytokine and the like at the above concentration) in a volume 2-foldgreater than the sampled culture solution, and then returning thesuspension to each well. On day 6 of culturing, the cells werecollected, the cell number was calculated, and then the cells weresuspended at a concentration of 1×10⁶/ml in the above media. Anti-CD40antibodies or the isotype controls thereof were added to the media, andthen cultured for further 4 days in a 24-well plate. During this period,no culture exchange was performed (cell number per well of 1×10⁶ cells,and cell concentration of 1×10⁶/ml).

(3) Cell Staining and Analysis by Flow Cytometer

For staining, anti-HLA-DR antibodies (isotype control: rat IgG2a),anti-CD86 antibodies (isotype control: rat IgG1) and anti-CD83antibodies (isotype control: rat IgG2b) were used. First, the antibodieswere added, and then incubation was performed at 4° C. for 30 minutes.After 3 washings, analysis was performed using the FACS Calibur (BecktonDickinson).

(4) Increase in IL-12 Secretion Ability of Mature DC

After immature DC were obtained as described above, LPS (400 pg/ml) andIFNγ (10⁻³M) were added, and then culturing was performed for 2 days,thereby obtaining mature DC. To the mature DC, 10 μg/ml anti-CD40antibodies or the isotype control was added. For the supernatant after24 hours, IL-12 production was measured using ELISA (Pharmingen).

(5) Results and Discussion

FIG. 7 shows the effect of KM302-1 antibodies, the agonistic antibodies,on DC maturation, and FIG. 8 shows the effect of KM302-1 antibodies onIL-12 production of mature DC. The degree of maturation was comparedwith G28-5 antibodies as a control. When the expression of CD86 and thatof HLA-DR were examined, the expression was further elevated, that is,the degree of maturation was increased in the case of KM302-1 antibodiescompared with the case of G28-5 antibodies. It was also shown that IL-12secretion was increased by the treatment of mature DC with KM302-1antibodies. Accordingly, it was shown that the KM302-1 antibodies actedas agonistic antibodies on DC.

Example 10 DC-MLR

Blood (peripheral blood) collected from a normal human was centrifugedat 2000 rpm for 10 minutes, and then the serum was absorbed. The bloodcell fraction was re-suspended with PBS, and then gently placed onFicoll (Amersham Pharmacia). Centrifugation was performed at 2000 rpmfor 30 minutes, so that a PBMC portion in the intermediate layer wascollected, washed twice with PBS, and then used for a certain cellseparation process using MACS.

Monocyte separation for culturing DC was performed according to theattached instruction using MACS (Miltenyi Biotec GmbH). This is brieflyexplained as follows. 800 μl of MACS Buffer and 200 μl of MACS CD14(Miltenyi Biotec GmbH, 502-01) were added to PBMC (1×10⁸), and thentreated at 4° C. for 15 minutes. The cells were adsorbed to a MACS LScolumn, and then washed. The cells adsorbed to the column were collectedas monocytes. MACS HLA-DR (Miltenyi Biotec GmbH, 461-01) was added tothe cells that were not adsorbed to the column. HLR-DR positive cellswere removed with a BS column, thereby preparing a T cell fraction. Theproportion of CD3 positive cells was measured by FACS, and thensubstantial number of T cells was calculated from the total cell numberin the T cell fraction. The obtained monocytes were cultured in R0 media(PPMI medium supplemented with β-mercapto ethanol (Gibco) and HEPES(SIGMA)) containing 100 ng/ml IL-4 (R&D system), 50 ng/ml G-CSF (KIRIN)and 10% FCS (SIGMA) at a concentration of 1×10⁶ cells/ml in a 6-wellculture plate. On day 5 after culturing, 10 ng/ml LPS (DIFCO) was addedfor the cells to differentiate into mature DC.

MLR was performed by mixing T cells and mature DC, which had beenisolated from different humans. The cell ratio of T cells to DC wasdetermined as 1:80, and number of T cells was determined as 2×10⁵cells/well. First, antibodies were added to DC for reaction to proceedfor 30 minutes. Subsequently, T cells were added, culturing wasperformed for 4 days, and then 10 μl of 100 μCi/ml ³H-Thymidine(Amersham Pharmacia) was added. 14 hours later, the cells were harvestedin Printed Filtermat A (Wallac) using a Macro 96 Harvester (SKATRON),dried, and then immersed well in Betap; Scint (Wallac). After packaging,activity was measured using a 1205 BETAPLATE liquid scintillationcounter. MLR using immature DC was performed by mixing T cells withmature DC, which had been isolated from different humans. With a cellratio of T cells to DC of 1:40, MLR was performed similarly. FIGS. 9 and10 show the results. It was shown that the addition of KM281-1-10antibodies lowered thymidine incorporation, and thus MLR could besuppressed. Furthermore, it was shown in FIG. 10 that KM283-5 and 5D12antibodies could not suppress DC-MLR. That is, only the KM281-1-10antibody is an antagonistic antibody that neutralizes the action of CD40ligands on DC. Moreover, FIG. 11 shows the results of examining theeffect of KM302-1 antibodies, which are agonistic antibodies, on MLRusing immature DC. Activation of DC promoted interaction with T cells,and caused an increase in thymidine incorporation. These resultsindicated that KM302-1 is an agonistic antibody that acts on immatureDC.

Example 11 Effect of CD40 Antibody on the Binding of CD40L to CD40

Anti-CD40 antibodies were caused to bind to immobilized CD40 human FCusing BIAcore 2000 (Biacore), and then changes in the binding amount ofsoluble CD40L to CD40 were measured. According to the instructionattached to the system, soluble CD40 human FC was immobilized on a CMchip (CM5, Biacore). Next, 25 μg/ml anti-CD40 antibodies were added tobind to CD40. Further, 10 μg/ml soluble CD40L was added for binding. Adifference between the binding amounts before and after addition ofCD40L was measured. When control IgG was added, the binding amount ofCD40L was 100 RU. After addition of KM302-1 antibodies, the bindingamount of CD40L was 110 RU, and after addition of KM283-5 antibodies thebinding amount of CD40L was 18RU. Thus, it was shown that the KM302-1antibody does not inhibit the binding of CD40L to CD40.

Example 12 Promotion of CD95 Expression in Ramos Cells by Anti-CD40Agonistic Antibody

Purified antibodies of the hybridomas obtained in Example 4 wereanalyzed according to the method of Example 6, and then clones producingagonistic antibodies were selected (number of cells per well: 5×10⁴;cell concentration: 2.5×10⁵/ml). FIG. 12 shows the results. In thefigure, the horizontal axis indicates the antibody concentration inculture solutions, and the longitudinal axis indicates averagefluorescence intensities, that is, CD95 expression intensities. At aconcentration of 0.01 μg/ml or more, KM341-1-19 and 2105 antibodies wereshown to promote CD95 expression of Ramos cells more effectively thanG28-5 antibodies, which are known mouse antibodies. Specifically,KM341-1-19 and 2105 antibodies were shown to be more effective agonisticantibodies. Further, the agonistic activity (to increase CD95 expressionof Ramos cells) of KM341-1-19 and 2105 antibodies (0.01 μg/ml) washigher than that of G28-5 antibodies (10 μg/ml) (FIG. 12). Table 5summarizes that at each antibody concentration, CD95 expression level ishow many times greater or less than that expressed by the addition ofG28-5 antibodies.

TABLE 5 Antibody concentration (μg/ml) KM341-1-19 2105 F5-77 F2-103 0.015.7 3.9 0.1 7.0 7.1 1.2 1.2 1 5.7 5.1 1.7 1.8 10 4.5 3.3 2.0 1.7

Example 13 Activation of Dendritic Cell by CD40 Agonistic Antibody

According to the method of Example 9, the effect of CD40 agonisticantibodies on IL-12 production and IL-10 production by mature DC wasexamined. IL-10 was measured by the ELISA (Pharmingen) method. FIGS. 13and 14 show the results. It was shown that IL-12 secretion was increasedby treatment with KM341-1-19 antibodies. In contrast, even when CD40ligand-expressing recombinant L cells (2×10⁵ cells/ml) that had beenirradiated with X-rays (5000 rad) were allowed to co-exist, theconcentrations of IL-12 and IL-10 in culture solutions were 254 and 51pg/ml, respectively. They were lower than that when 1 μg/ml KM341-1-19antibodies were added.

As described above, it was shown that KM341-1-19 antibodies act on DC aseffective agonistic antibodies. The agonistic activity of KM341-1-19antibodies (0.1 μg/ml) to cause mature DC to secrete IL-12 was higherthan that of G28-5 antibodies (100 μg/ml). The agonistic activity ofKM341-1-19 antibodies (1 μg/ml) to cause mature DC to secrete IL-12 was100 times or more greater than that by G28-5 antibodies (100 μg/ml)(FIG. 13). Furthermore, the agonistic activity of KM341-1-19 antibodies(1 μg/ml) to cause mature DC to secrete IL-10 was 10 times or moregreater than that by G28-5 antibodies (100 μl/ml) (FIG. 14). Moreover,since the subclass of KM341-1-19 antibody was IgG2, the antibody haslower binding ability to the Fc receptor than that of IgG1 or IgG3. Itsability to sensitize the killer activity of NK cells and ability toactivate the complement system are also weak. Accordingly, there may bea low risk that the function of CD40-expressing cells or the number ofthe cells themselves decreases due to the antibody. Furthermore, theantibody is not easily cross-linked by an Fc receptor, so that it can beexpected that the drug effect is easily controlled without any largefluctuation in in vivo agonistic activity due to cross-linking.

Example 14 Suppression of CD95 Expression in Ramos Cells by Anti-CD40Antagonistic Antibody

1.0×10⁶ cells/ml Ramos cell suspension was inoculated at 50 μl/well to aflat bottom 96-well plate (number of cells per well: 5×10⁴). Purifiedantibodies diluted with media were added at 100 μl/well to a 96-wellplate. Human CD40 ligand-expressing recombinant mouse L cells (seeSpriggs, M. K. et. al., J. Exp. Med., 176: 1543, 1992; Garrone, P. et.al., J. Exp. Med., 182: 1265, 1995 and the like) were prepared at1.0×10⁵ cells/ml. The prepared cells were added at 50 μl/well (thenumber of Ramos cells per well: 5×10⁴; Ramos cell concentration: 2.5×10⁴cells/ml; the number of mouse L cells per well: 5×10³; mouse cellconcentration: 2.5×10⁴ cells/ml). After overnight culture, the cellswere collected, and then analyzed by FACS using R-PE-labeled anti-CD95antibodies. FIG. 15 shows the results. In the figure, the longitudinalaxis indicates the average fluorescence intensity, that is, CD95expression intensity. Whereas the known 5D12 antibodies suppressed theexpression slightly, 4D11 antibodies suppressed, even at a concentrationof 0.1 μg/ml, CD95 expression to the same degree as that of a case of anegative control wherein no CD40L-expressing cells had been added.Moreover, at a concentration of 1 μg/ml, 4D11, F4-465 and KM281-1-10suppressed CD95 expression to the same degree as that of the case of thenegative control wherein no CD40L-expressing cells had been added. Theseresults showed that 4D11, F4-465 and KM281-1-10 antibodies are moreeffective antagonistic antibodies. Table 6 shows relative values of theaverage fluorescence intensity corresponding to each antibodyconcentration, when the value of the control case wherein noantagonistic antibodies were added is determined as 100.

TABLE 6 Antibody concentration (μg/ml) 5D12 4D11 F4-465 KM281-1-10 0.177.6 11.8 49.6 60.1 1 72.3 0.01 2.5 7.3 10 69.5 0 1.1 2.6

Example 15 Anti-Tumor Effect in Ramos Cell Transplantation Model byAnti-CD40 Agonistic Antibody

Anti-asialo GM1 antibodies were intravenously injected to 5-week-oldC.B.17/Icr-scidJc1 mice (CLEA JAPAN). 1 day later, 5×10⁶ Ramos cells permouse were intravenously injected as tumor cells. 1 day later, KM302-1antibodies or anti-human albumin human IgG antibodies as a negativecontrol were intravenously injected. The doses per mouse of KM302-1antibodies were 1, 10 and 100 μg, and the same of the negative controlantibodies was 100 μg. Each of these antibodies was administered once to5 mice. FIG. 16 shows the results. By day 34 after transplantation, allthe mice of the negative control-administered group had died, whereasall the 5 mice each of the groups administered with 10 μg and 100 μg ofKM302-1 antibodies had been administered to which survived. Thus, theanti-tumor effect of KM302-1 antibodies was confirmed. The KM302-1antibody is of the IgG4 subclass, so that the Fc receptor-mediatedantibody dependent cellular cytotoxicity (ADCC) and activation of thecomplement system are weak. Despite these characteristics, it wasobserved that single administration of 10 μg of KM302-1 antibodiesprolonged the survival time of tumor-bearing mice.

Example 16 Ramos Cell Proliferation Suppression by Anti-CD40 AgonisticAntibody

A Ramos cell suspension was prepared at 1×10⁴ cells/ml in an RPMI1640medium supplemented with 10% FBS, and then 100 μl of the suspension wasapportioned to a 96-well plate. A KM341-1-19 antibody or soluble ligandsolution prepared at 20 μg/ml using media was added. Anti-FLAGantibodies (M2) with the same concentration as that of the ligands wereallowed to co-exist with the soluble ligands (the concentration in thereaction solution was 10 μg/ml), thereby enhancing the activity. After 5days of culturing, 20 μl of MTS reagent (Promega) was added to eachwell, and then allowed to react for 2 to 3 hours. Differences inabsorbance between the cell-free and antibody-free wells and the cell-and antibody-containing wells were measured at a wavelength of 490 nm,thereby measuring viable cell count. Furthermore, theproliferation-suppressing action was compared with that of G28-5antibodies using a 96-well U-bottomed plate similarly. KM341-1-19antibodies or G28-5 antibodies prepared at 2 μg/ml using media wereadded. FIG. 17 shows the results. In wells to which KM341-1-19antibodies had been added, dead cells were observed, the cell number wassignificantly lower than those of wells to which G28-5 antibodies or theligands had been added, and the absorbance was also low. These resultsindicate that the proliferation of tumor cells was suppressed, and celldeath was induced.

Example 17 cDNA Cloning of Antibody Gene

Hybridomas producing KM341-1-19, 2105, 110, 115, KM281-1-10, 4D11,KM643-4-11, F4-465, F2-103 and F5-77 antibodies were cultured, and thenthe cells were collected by centrifugation. TRIZOL (Gibco BRL) was addedto the cells, and then Total RNA was extracted according to the attachedinstructions. Cloning of the variable regions of the antibody cDNA wasperformed according to the attached instructions using a SMART RACE cDNAamplification Kit (CLONTECH). Using 5 μg of total RNA as a template, 1stStrand cDNA was constructed. To amplify the heavy chains (H chain) ofKM341-1-19, 2105, 110, 115, KM281-1-10, 4D11, KM643-4-11, F2-103 andF5-77, Z-Taq (Takara) and UMP and hh6 primers were used, and a cycle of98° C. for 1 second and 68° C. for 30 seconds was repeated 30 times.Furthermore, using 1 μl of the reaction solution as a template and NUMPand hh3 primers, a cycle of 98° C. for 1 second and 68° C. for 30seconds was repeated 20 times. To amplify a F4-465 heavy chain, UMP andhh2 primers and an Advantage 2 PCR kit (Clonthech, cat#1910) were used,and 5 cycles of 94° C. for 5 seconds and 72° C. for 3 minutes, 5 cyclesof 94° C. for 5 seconds, 70° C. for 0 seconds and 72° C. for 3 minutes,and 25 cycles of 94° C. for 5 seconds, 68° C. for 10 seconds and 72° C.for 3 minutes were performed.

hh6 primer: (SEQ ID NO: 3) 5′-GGT CCG GGA GAT CAT GAG GGT GTC CTT-3′ hh3primer: (SEQ ID NO: 4) 5′-GTG CAC GCC GCT GGT CAG GGC GCC TG-3′ hh2primer: (SEQ ID NO: 5) 5′-GCT GGA GGG CAC GGT CAC CAC GCT G-3′

Subsequently, the amplified PCR product was purified using a PCRpurification kit (QIAGEN), and then the nucleotide sequence wasdetermined using hh4 as a primer. Alternatively, the product wassubcloned to PCR-Script (Stratagene, Lajolla, Calif.) or PCR-Blunt(Invitrogene, Carlsbad, Calif.), and then sequencing was performed.Based on the sequence information, antibody heavy-chain-specific primerswere synthesized. A 341H primer was synthesized in the case ofKM341-1-19, a 2105Hsa1 primer in the case of 2105, a 110Hsa1 primer inthe case of 110 and 115, a 2811Hsa1 primer in the case of KM281-1-10, a4D11Sa1 primer in the case of 4D11, a 643Hsa1 primer in the case ofKM643-4-11, H11-95′ primer in the case of F4-465, a F2-103H primer inthe case of F2-103 and F5-77H primer in the case of F5-77. Using theantibody heavy chain specific primers and hh4, cDNA was amplified fromthe 1st Strand cDNA, and then the sequence from the opposite directionwas determined using the amplified product as a template and theantibody-specific primers.

hh4 primer: (SEQ ID NO: 6) 5′-GGTGCCAGGGGGAAGACCGATGG-3′ 341 H primer:(SEQ ID NO: 7) 5′-atatgtcgacGCTGAATTCTGGCTGACCAGGGCAG-3′ 2105Hsal: (SEQID NO: 8) atatgtcgacTCCCAGGTGTTTCCATTCAGTGATCAG 110Hsal: (SEQ ID NO: 9)atatgtcgacTTCCATTCGGTGATCAGCACTGAACAC 281Hsal: (SEQ ID NO: 10)atatgtcgacTTTGAGAGTCCTGGACCTCCTGTG 4D11Sal: (SEQ ID NO: 11)atatgtcgacGAGTCATGGATCTCATGTGCAAG 643Hsal: (SEQ ID NO: 12)atatgtcgacCCAGGGCAGTCACCAGAGCTCCAGAC H11-9 5′: (SEQ ID NO: 13) ACC GTGTCG ACT ACG CGG GAG TGA CT F2-103 H: (SEQ ID NO: 14)accgtgtcgacgctgatcaggactgcaca F5-77 H: (SEQ ID NO: 15)accgtgtcgacggtgatcaggactgaacag

The light chains (L chains) of KM341-1-19, 2105, 110, 115, KM281-1-10,4D11, KM643-4-11, F2-103 and F5-77 were amplified using UMP and hk2primers and by repeating 30 times a cycle of 98° C. for 1 second and 68°C. for 30 seconds. The light chain of F4-465 was amplified using UMP andhL2 primers and by repeating 30 times a cycle of 98° C. for 1 second and68° C. for 30 seconds. The amplified PCR product was purified using aPCR purification kit, and then the nucleotide sequence was determinedusing hk6 or hL2 primers. Based on the sequences, light chain specificprimers were synthesized. A 341K primer was synthesized in the case ofKM341-1-19, 2053 KBg1 primer in the case of 2105, 110 KBg1 primer in thecase of 110 and 115, 281 KBg1 primer in the case of KM281-1-10, 4D11KBg1in the case of 4D11, 643 KBg1 primer in the case of KM643-4-11, Lamda 5′primer in the case of F4-465, and F2-103K primer in the case of F-103and F5-77.

In the case of 341-1-19, 110, 115, KM643-4-11, KM281-1-10, 4D11 and2105, cDNA was amplified from the 1st Strand cDNA using the light chainspecific primer and hk6 primer. The sequence was then determined fromboth directions using the amplified product as a template. For F4-465,F2-103 and F5-77, subcloning to PCR-Script (Stratagene, Lajolla, Calif.)or PCR-Blunt (Invitrogene, Carlsbad, Calif.) was performed to determinethe sequence.

hk2 primer: (SEQ ID NO: 16) 5′-GTT GAA GCT CTT TGT GAC GGG CGA GC-3′ hL2primer: (SEQ ID NO: 17) 5′-TCT TCT CCA CGG TGC TCC CTT CAT-3′ 341Kprimer: (SEQ ID NO: 18) 5′-atatagatctGAACTGCTCAGTTAGGACCCAGAGG-3′2053KBgl: (SEQ ID NO: 19) atatagatctCGCGGGGAAGGAGACTGCTCAGTT 110KBgl:(SEQ ID NO: 20) atatagatctAGTCAGACCCAGTCAGGACACAGC 281KBgl: (SEQ ID NO:21) atatagatctGAGCTGCTCAGTTAGGACCCAGAGGG 4D11KBgl: (SEQ ID NO: 22)atatagatctTAAGCAAGTGTAACAACTCAGAGTAC 643KBgl: (SEQ ID NO: 23)atatagatctGAGGAACTGCTCAGTTAGGACCCAGAGG Lamda 5′: (SEQ ID NO: 24)AACTCCAGATCTGCCTCAGGAAGCAGCATC F2-103 K: (SEQ ID NO: 25)aactccagatctagggcaagcagtggtaac hk6 primer: (SEQ ID NO: 26)5′-TGGCGGGAAGATGAAGACAGATGGTG-3′

DNAs of 341-1-19 encoding the full-length H-chain and L-chain variableregions and the amino acid sequences of H-chain and L-chain arerespectively shown below.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 50th adenine (A) from the 5′ end of SEQ ID NO: 27, andthe termination codon is TGA beginning from the 1472nd thymine (T). Theboundary of the antibody variable region and the constant region islocated between the 493rd adenine (A) and the 494th guanine (G) from the5′ end. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus to the 148th serine (S) residue of SEQ ID NO: 28,and the constant region is of the 149th alanine (A) and the followingresidues. It was predicted by a gene sequence prediction software(Signal P ver.2) that the H-chain signal sequence ranges from theN-terminus to the 20th serine (S) of SEQ ID NO: 28. It is thought thatthe N-terminus of the mature protein is the 21st glutamine (Q) of SEQ IDNO: 28.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 29th A from the 5′ end of SEQ ID NO: 29, and thevariable region ranges from the 5′ end to the 400th adenine (A). In theamino acid sequence, the variable region ranges from the N-terminus tothe 124th lysine (K) of SEQ ID NO: 30. Analysis of the N-terminus of thepurified L-chain protein revealed that the L-chain signal sequenceranges from the N-terminus to the 20th glycine (G) of SEQ ID NO: 30, andthe N-terminus of the mature protein is the 21st glutamic acid (E) ofSEQ ID NO: 30.

341-1-19 H-chain (SEQ ID NO: 27):GTCGACGCTGAATTCTGGCTGACCAGGGCAGCCACCAGAGCTCCAGACAATGTCTGTCTCCTTCCTCATCTTCCTGCCCGTGCTGGGCCTCCCATGGGGTGTCCTGTCACAGGTCCAACTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTACTTGGAACTGGATCAGGCAGTCCCCATCGAGAGACCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATCGTGATTATGTAGGATCTGTGAAAAGTCGAATAATCATCAACCCAGACACATCCAACAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTATATATTACTGTACAAGAGCACAGTGGCTGGGAGGGGATTACCCCTACTACTACAGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCCAGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTTGTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACACCTCCCATGCTGGACTCAGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGGATCC 341-1-19 H-chain amino acid sequence (SEQID NO: 28) MSVSFLIFLPVLGLPWGVLSQVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSATWNWIRQSPSRDLEWLGRTYYRSKWYRDYVGSVKSRIIINPDTSNNQFSLQLNSVTPEDTAIYYCTRAQWLGGDYPYYYSMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 341-1-19 L-chain (SEQ ID NO: 29):ACTGCTCAGTTAGGACCCAGAGGGAACCATGGAAGCCCCAGCTCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACACTTTCGGCCCTGGGACCAAAGTGGATATCAAA CGTACG 341-1-19L-chain amino acid sequence (SEQ ID NO: 30)MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNTFGPGTKVDIKRT

DNAs of 2105 encoding the H-chain variable region and L-chain variableregion and the amino acid sequences of the H-chain and L-chain are shownbelow.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 70th adenine (A) from the 5′ end of SEQ ID NO: 31. Theboundary of the antibody variable region and the constant region islocated between the 495th adenine (A) and the 496th guanine (G) from the5′ end. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus to the 142nd serine (S) residue of SEQ ID NO: 32,and the constant region is of the 149th alanine (A) and the followingresidues. It was predicted by a gene sequence prediction software(Signal P ver.2) that the H-chain signal sequence ranges from theN-terminus to the 19th cystein (C) of SEQ ID NO: 32. It is thought thatthe N-terminus of the mature protein is the 20th glutamic acid (E) ofSEQ ID NO: 32.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 28th A from the 5′ end of SEQ ID NO: 33, and thevariable region ranges from the 5′ end to the 405th adenine (A). In theamino acid sequence, the variable region ranges from the N-terminus tothe 126th lysine (K) of SEQ ID NO: 34. It was predicted by gene sequenceprediction software (Signal P ver.2) that the L-chain signal sequenceranges from the N-terminus to the 20th glycine (G) of SEQ ID NO: 34. Itis thought that the N-terminus of the mature protein is the 21stglutamic acid (E) of SEQ ID NO: 34.

2105 H-chain (SEQ ID NO: 31)CTGAACACAGACCCGTCGACTCCCAGGTGTTTCCATTCAGTGATCAGCACTGAACACAGAGGACTCACCATGGAGTTGGGACTGAGCTGGATTTTCCTTTTGGCTATTTTAAAAGGTGTCCAGTGTGAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCTCAGGTATTAGTTGGAATAGTGGTAGCTTGGTGCATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGTGCAAGAGATAGGCTATTTCGGGGAGTTAGGTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAG CACCAAGG 2105 H-chainamino acid sequence (SEQ ID NO: 32)MELGLSWIFLLAILKGVQCEVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSLVHADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDRLFRGVRYYGMDVWGQGTTVTVSSASTK 2105 L-chain (SEQ ID NO:33) CTGCTCAGTTAGGACCCAGAGGGAACCATGGAAGCCCCAGCTCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCGAGATACCACCGGAGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCACTTTATTACTGTCAGCAGCGTAGCCACTGGCTCACTTTCGGCGGGGGGACCAAGGTGGAGA TCAAACGTACGGTG 2105L-chain amino acid sequence (SEQ ID NO: 34)MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSHWLTFGGGTKVEIKRTV

DNAs of 110 encoding the H-chain variable region and L-chain variableregion and the amino acid sequences of the H-chain and L-chain arerespectively shown below.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 60th adenine (A) from the 5′ end of SEQ ID NO: 35. Theboundary of the antibody variable region and the constant region islocated between the 479th adenine (A) and the 480th guanine (G) from the5′ end. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus of SEQ ID NO: 36 to the 140th serine (S) residue,and the constant region is of the 141st alanine (A) and the followingresidues. It was predicted by gene sequence prediction software (SignalP ver.2) that the H-chain signal sequence ranges from the N-terminus tothe 19th cystein (C) of SEQ ID NO: 36. It is thought that the N-terminusof the mature protein is the 20th glutamine (Q) of SEQ ID NO: 36.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 35th A from the 5′ end of SEQ ID NO: 37, and thevariable region ranges from the 5′ end to the 421st adenine (A). In theamino acid sequence, the variable region ranges from the N-terminus tothe 129th lysine (K) of SEQ ID NO: 38. It was predicted by gene sequenceprediction software (Signal P ver.2) that the L-chain signal sequenceranges from the N-terminus to the 22nd cystein (C) of SEQ ID NO: 38. Itis thought that the N-terminus of the mature protein is the 23rd valine(V) of SEQ ID NO: 38.

110 H-chain (SEQ ID NO: 35)CTGAACACAGACCCGTCGACTTCCATTCGGTGATCAGCACTGAACACAGAGGACTCACCATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTATTAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAGGGCTACAATATTTTGACTGGTTATTTTGGCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGG 110 H-chain amino acidsequence (SEQ ID NO: 36)MEFGLSWVFLVALLRGVQCQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGYNILTGYFGYWGQGTLVTVSSASTK 110 L-chain (SEQ ID NO: 37)TCACAGATCTAGTCAGACCCAGTCAGGACACAGCATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTCCTGCTGCTCTGGCTCCCAGGTGCCAGATGTGTCATCTGGATGACCCAGTCTCCATCCTTACTCTCTGCATCTACAGGAGACAGAGTCACCATCAGTTGTCGGATGAGTCAGGGCATTAGCAGTGATTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTGAGCTCCTGATCTCTGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCTGCCTGCAGTCTGAAGATTTTGCAACTTATTACTGTCAACAGTATTATAGTTTTCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGTACG 110 L-chain amino acid sequence (SEQ ID NO:38) MDMRVPAQLLGLLLLWLPGARCVIWMTQSPSLLSASTGDRVTISCRMSQGISSDLAWYQQKPGKAPELLISAASTLQSGVPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQYYSFPWTFGQGTKVEIKRT

DNAs of 115 encoding the H-chain variable region and L-chain variableregion and the amino acid sequences of the H-chain and L-chain arerespectively shown below.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 60th adenine (A) from the 5′ end of SEQ ID NO: 39. Theboundary of the antibody variable region and the constant region islocated between the 479th adenine (A) and the 480th guanine (G) from the5′ end. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus of SEQ ID NO: 40 to the 140th serine (S) residue,and the constant region is of the 141st alanine (A) and the followingresidues. It was predicted by gene sequence prediction software (SignalP ver.2) that the H-chain signal sequence ranges from the N-terminus tothe 19th cystein (C) of SEQ ID NO: 40. It is thought that the N-terminusof the mature protein is the 20th glutamine (Q) of SEQ ID NO: 40.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 35th A from the 5′ end of SEQ ID NO: 41, and thevariable region ranges from the 5′ end to the 421st adenine (A). In theamino acid sequence, the variable region ranges from the N-terminus tothe 129th lysine (K) of SEQ ID NO: 42. It was predicted by gene sequenceprediction software (Signal P ver.2) that the L-chain signal sequenceranges from the N-terminus to the 22nd cystein (C) of SEQ ID NO: 42. Itis thought that the N-terminus of the mature protein is the 23rd valine(V) of SEQ ID NO: 42.

115 H-chain (SEQ ID NO: 39)CTGAACACAGACCCGTCGACTTCCATTCGGTGATCAGCACTGAACACAGAGGACTCACCATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGGCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGAATGATGGAAGTATTAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAGGGCTACAATATTTTGACTGGTTATTTTGGCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGG 115 H-chain amino acidsequence (SEQ ID NO: 40)MEFGLSWVFLVALLRGVQCQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWNDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGYNILTGYFGYWGQGTLVTVSSASTK 115 L-chain (SEQ ID NO: 41)TCACAGATCTAGTCAGACCCAGTCAGGACACAGCATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTCCTGCTGCTCTGGCTCCCAGGTGCCAGATGTGTCATCTGGATGACCCAGTCTCCATCCTTACTCTCTGCATCTACAGGAGACAGAGTCACCATCAGTTGTCGGATGAGTCAGGGCATTAGCAGTGATTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTGAGCTCCTGATCTCTGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCTGCCTGCAGTCTGAAGATTTTGCAACTTATTACTGTCAACAGTATTATAGTTTTCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGTACG 115 L-chain amino acid sequence (SEQ ID NO:42) MDMRVPAQLLGLLLLWLPGARCVIWMTQSPSLLSASTGDRVTISCRMSQGISSDLAWYQQKPGKAPELLISAASTLQSGVPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQYYSFPWTFGQGTKVEIKRT

DNAs of 281-1-10 encoding the H-chain variable region and L-chainvariable region and the amino acid sequences of the H-chain and L-chainare respectively shown below.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 52nd adenine (A) from the 5′ end of SEQ ID NO: 43. Theboundary of the antibody variable region and the constant region islocated between the 468th adenine (A) and the 469th guanine (G) from theSend. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus of SEQ ID NO: 44 to the 139th serine (S) residue,and the constant region is of the 140th alanine (A) and the followingresidues. It was predicted by gene sequence prediction software (SignalP ver.2) that the H-chain signal sequence ranges from the N-terminus tothe 19th serine (S) of SEQ ID NO: 44. It is thought that the N-terminusof the mature protein is the 20th glutamine (Q) of SEQ ID NO: 44.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 41 st A from the 5′ end of SEQ ID NO: 45, and thevariable region ranges from the 5′ end to the 424th adenine (A). In theamino acid sequence, the variable region ranges from the N-terminus tothe 128th lysine (K) of SEQ ID NO: 46. It was predicted by gene sequenceprediction software (Signal P ver.2) that the L-chain signal sequenceranges from the N-terminus to the 20th glycine (G) of SEQ ID NO: 46. Itis thought that the N-terminus of the mature protein is the 21stglutamic acid (E) of SEQ ID NO: 46.

281-1-10 H-chain (SEQ ID NO: 43)CTGAACACAGACCCGTCGACTTTGAGAGTCCTGGACCTCCTGTGCAAGAACATGAAACATCTGTGGTTCTTCCTTCTCCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTGGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTATTACAGTGGGAGCACCAACTACAATCCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAATTCTGTGACCGCTGCGGACACGGCCGTGTATTACTGTGCGAGAGCCCCCTTGCACGGTGACTACAAATGGTTCCACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGG 281-1-10 H-chain amino acid sequence(SEQ ID NO: 44) MKHLWFFLLLVAAPRWVLSQVQLQESGPGLVKPSETLSLTCTVSGGSISGYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARAPLHGDYKWFHPWGQGTLVTVSSASTK 281-1-10 L-chain (SEQ ID NO:45) TCACAGATCTGAGCTGCTCAGTTAGGACCCAGAGGGAACCATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCGATCACCTTCGGCCAAGGGACACGACTGGAGATCAAACGTACG 281-1-10 L-chain amino acid sequence (SEQID NO: 46) METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIKRT

DNAs of 4D11 encoding the H-chain variable region and L-chain variableregion and the amino acid sequences of the H-chain and L-chain arerespectively shown below.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 16th adenine (A) from the 5′ end of SEQ ID NO: 47. Theboundary of the antibody variable region and the constant region islocated between the 456th adenine (A) and the 457th guanine (G) from the5′ end. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus of SEQ ID NO: 48 to the 147th serine (S) residue,and the constant region is of the 148th alanine (A) and the followingresidues. It was predicted by gene sequence prediction software (SignalP ver.2) that the H-chain signal sequence ranges from the N-terminus tothe 26th serine (S) of SEQ ID NO: 48. It is thought that the N-terminusof the mature protein is the 27th glutamine (Q) of SEQ ID NO: 48.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 59th A from the 5′ end of SEQ ID NO: 49, and thevariable region ranges from the 5′ end to the 442nd adenine (A). In theamino acid sequence, the variable region ranges from the N-terminus tothe 128th lysine (K) of SEQ ID NO: 50. It was predicted by gene sequenceprediction software (Signal P ver.2) that the L-chain signal sequenceranges from the N-terminus to the 22nd cystein (C) of SEQ ID NO: 50. Itis thought that the N-terminus of the mature protein is the 21st alanine(A) of SEQ ID NO: 50.

4D11 H-chain (SEQ ID NO: 47)ATATGTCGACGAGTCATGGATCTCATGTGCAAGAAAATGAAGCACCTGTGGTTCTTCCTCCTGCTGGTGGCGGCTCCCAGATGGGTCCTGTCCCAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTACTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGCGGCTCCATCAGCAGTCCTGGTTACTACGGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTATAAAAGTGGGAGCACCTACCACAACCCGTCCCTCAAGAGTCGAGTCACCATATCCGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTACTGTACGAGACCTGTAGTACGATATTTTGGGTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTC TCCTCAGCTAGC 4D11H-chain amino acid sequence (SEQ ID NO: 48)MDLMCKKMKHLWFFLLLVAAPRWVLSQLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGSTYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQGTLVTVSSAS 4D11 L-chain (SEQ IDNO: 49) AGATCTTAAGCAAGTGTAACAACTCAGAGTACGCGGGGAGACCCACTCAGGACACAGCATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCAGATGTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAATTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGTACG 4D11 L-chain amino acidsequence (SEQ ID NO: 50)MDMRVPAQLLGLLLLWLPGARCAIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIKRT

DNAs of KM643-4-11 encoding the H-chain variable region and L-chainvariable region and the amino acid sequences of the H-chain and L-chainare respectively shown below.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 1st adenine (A) from the 5′ end of SEQ ID NO: 51. Theboundary of the antibody variable region and the constant region islocated between the 447th adenine (A) and the 448th guanine (G) from the5′ end. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus of SEQ ID NO: 52 to the 149th serine (S) residue,and the constant region is of the 150th alanine (A) and the followingresidues. It was predicted by gene sequence prediction software (SignalP ver.2) that the H-chain signal sequence ranges from the N-terminus tothe 20th serine (S) of SEQ ID NO: 52. It is thought that the N-terminusof the mature protein is the 21st glutamine (Q) of SEQ ID NO: 52.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 38th A from the 5′ end of SEQ ID NO: 53, and thevariable region ranges from the 5′ end to the 409th adenine (A). In theamino acid sequence, the variable region ranges from the N-terminus tothe 124th lysine (K) of SEQ ID NO: 54. It was predicted by gene sequenceprediction software (Signal P ver.2) that the L-chain signal sequenceranges from the N-terminus to the 20th glycine (G) of SEQ ID NO: 54. Itis thought that the N-terminus of the mature protein is the 21stGlutamic acid (E) of SEQ ID NO: 54.

KM643-4-11 H-chain (SEQ ID NO: 51)ATGTCTGTCTCCTTCCTCATCTTCCTGCCCGTGCTGGGCCTCCCATGGGGTGTCCTGTCACAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCATTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCAGGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGTATAAAGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAGAACCAGTTCTCCCTGCAGCTGAACTCTGTGACCCCCGAGGACACGGCTGTGTATTACTGTGCAAGAGGGTATTACTATGGTTCGGGGAGCTATCCCTACTACTACCAAATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCT AGC KM643-4-11H-chain amino acid sequence (SEQ ID NO: 52)MSVSFLIFLPVLGLPWGVLSQVQLQQSGPGLVKPSQTLSFTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYKDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARGYYYGSGSYPYYYQMDVWGQGTTVTVSSA S KM643-4-11 L-chain(SEQ ID NO: 53) AATTGAGGAACTGCTCAGTTAGGACCCAGAGGGAACCATGGAAGCCCCAGCTCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGTGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACACTTTCGGCGGAGGGACCAAGGTG GAGATCAAACGAACKM643-4-11 L-chain amino acid sequence (SEQ ID NO: 54)MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGESATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNTFGGGTKVEIKR

DNAs of F4-465 encoding the H-chain variable region and L-chain variableregion and the amino acid sequences of the H-chain and L-chain arerespectively shown below.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 47th adenine (A) from the 5′ end of SEQ ID NO: 55. Theboundary of the antibody variable region and the constant region islocated between the 484th adenine (A) and the 445th guanine (G) from the5′ end. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus of SEQ ID NO: 56 to the 146th serine (S) residue,and the constant region is of the 147th alanine (A) and the followingresidues. It was predicted by gene sequence prediction software (SignalP ver.2) that the H-chain signal sequence ranges from the N-terminus tothe 19th serine (S) of SEQ ID NO: 56. It is thought that the N-terminusof the mature protein is the 20th glutamine (Q) of SEQ ID NO: 56.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 81st A from the 5′ end of SEQ ID NO: 57, and thevariable region ranges from the 5′ end to the 440th (C). In the aminoacid sequence, the variable region ranges from the N-terminus to the120th Threonine (T) of SEQ ID NO: 58. It was predicted by gene sequenceprediction software (Signal P ver.2) that the L-chain signal sequenceranges from the N-terminus to the 19th alanine (G) of SEQ ID NO: 58. Itis thought that the N-terminus of the mature protein is the 20th serine(S) of SEQ ID NO: 58.

F4-465 H-chain (SEQ ID NO: 55)CTGAACACAGACCCGTCGACTACGCGGGAGACCACAGCTCCACACCATGGACTGGACCTGGAGGATCCTATTCTTGGTGGCAGCAGCAACAGGTGCCCACTCCCAGGTGCAGCTGGTGCAATCTGGGTCTGAGTTGAAGAAGCCTGGGGCCTCAGTGAAGGTCCCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGAATTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACACCAACACTGGGAACCCAACGTATGCCCAGGGCTTCACAGGACGGTTTGTCTTCTCCTTGGACACCTCTGTCAGCACGGCATATCTGCAGATCAGCAGCCTAAAGGCTGAGGACACTGCCGTGTATTACTGTGCGAGAGAGGTAGTACCAGTTGCTATGAGGGTAACTCACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAA F4-465 H-chain amino acidsequence (SEQ ID NO: 56)MDWTWRILFLVAAATGAHSQVQLVQSGSELKKPGASVKVPCKASGYTFTSYAMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCAREVVPVAMRVTHYYYGMDVWGQGTTVTVSSAST F4-465 L-chain (SEQ IDNO: 57) CTGGGTACGGTAACCGTCAGATCGCCTGGAGACGCCATCACAGATCTGCCTCAGGAAGCAGCATCGGAGGTGCCTCAGCCATGGCATGGATCCCTCTCTTCCTCGGCGTCCTTGTTTACTGCACAGGATCCGTGGCCTCCTATGAGCTGACTCAGCCACCCTCAGTGTCCGTGGCCCCAGGACAGACAGCCAGCATCACCTGTTCTGGAGATAAATTGGGGGATAATTTTACTTGCTGGTATCAGCAGAAGCCAGGCCAGTCCCCTGTGCTGGTCATCTTTCAGGATTGGAAGCGGCGCCCAGGGATCCCTGCGCGATTCTCTGGCTCCAAGTCTGGGAACACAGCCACTCTGACCATCAGCGGGACCCAGGCTATGGATGAGGCTGACTATTACTGTCAGGCGTGGGACATCAGCACTGTGGTATTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCATGAATTCAGATCCGTTAACGGTTACCAACTACCTAGACTGGATTCGTGACCAACATA F4-465 L-chain amino acid sequence (SEQID NO: 58) MAWIPLFLGVLVYCTGSVASYELTQPPSVSVAPGQTASITCSGDKLGDNFTCWYQQKPGQSPVLVIFQDWKRRPGIPARFSGSKSGNTATLTISGTQAMDEADYYCQAWDISTVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

DNAs of F2-103 encoding the H-chain variable region and L-chain variableregion and the amino acid sequences of the H-chain and L-chain arerespectively shown below.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 32nd adenine (A) from the 5′ end of SEQ ID NO: 59. Theboundary of the antibody variable region and the constant region islocated between the 463rd adenine (A) and the 464th Guanine (G) from the5′ end. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus of SEQ ID NO: 60 to the 144th Serine (S) residue,and the constant region is of the 145th Alanine (A) and the followingresidues. It was predicted by gene sequence prediction software (SignalP ver.2) that the H-chain signal sequence ranges from the N-terminus tothe 19th Cystein (C) of SEQ ID NO: 60. It is thought that the N-terminusof the mature protein is the 20th Glutamic acid (E) of SEQ ID NO: 60.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 29th A from the 5′ end of SEQ ID NO: 61, and thevariable region ranges from the 5′ end to the 415th adenine (A). In theamino acid sequence, the variable region ranges from the N-terminus tothe 129th Lysine (K) of SEQ ID NO: 62. It was predicted by gene sequenceprediction software (Signal P ver.2) that the L-chain signal sequenceranges from the N-terminus to the 22nd Cystein (C) of SEQ ID NO: 62. Itis thought that the N-terminus of the mature protein is the 23rd Asp (D)of SEQ ID NO: 62.

F2-103 H-chain (SEQ ID NO: 59)GCTGATCAGGACTGCACACAGAGAACTCACCATGGAGTTTGGGCTGAGCTGGGTTTTCCTTGTTGCTATTTTAAAAGGTGTCCAGTGTGAGGTGCAGCTGGTGGAGTCCGGGGGAGGCTTAGTTCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGTCTCTGGATTCACCTTCAGTACCTACTGGATGCACTGGGTCCGCCAAGCTCCAGGGAAGGGGCTGGTGTGGGTCTCACGTATTAATAGTGATGGGAGTAGCACAACCTACGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACGCTGTATCTGCAAATGAACAGTCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCAAGAGATAGAGTACTATGGATCGGGGAGTTATCCTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCAC CCTCCTCCAAGAGCACCTCTF2-1103 H-chain amino acid sequence (SEQ ID NO: 60)MEFGLSWVFLVAILKGVQCEVQLVESGGGLVQPGGSLRLSCAVSGFTFSTYWMHWVRQAPGKGLVWVSRINSDGSSTTYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARDRVLWIGELSYYGMDVWGQGTTVTVSSASTKGP SVFPLAPSSKSTS F2-103L-chain (SEQ ID NO: 61)GGGGAGTCAGACCCAGTCAGGACACAGCATGGACATGACGGTCCCCGCTCAGCTCCTGGGGCTCCTGCTGCTCTGGCTCCCAGGTGCCAAATGTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTAGTAACTGGTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGCTCTATAAGGCATCTGGTTTAGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAACAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGTCTAATAGTTATTCGTGGACGTTCGGCCACGGGACCAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGA F2-103 L-chain aminoacid sequence (SEQ ID NO: 62)MDMRVPAQLLGLLLLWLPGAKCDIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWYQQKPGKAPKLLLYKASGLESGVPSRFSGSGSGTEFTLTINSLQPDDFATYYCQQSNSYSWTFGHGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL

DNAs of F5-77 encoding the H-chain variable region and L-chain variableregion and the amino acid sequences of the H-chain and L-chain arerespectively shown below.

The translation initiation point of the H-chain DNA is an ATG codon thatbegins from the 100th adenine (A) from the 5′ end of SEQ ID NO: 63. Theboundary of the antibody variable region and the constant region islocated between the 528th adenine (A) and the 529th Guanine (G) from the5′ end. In the amino acid sequence, the H-chain variable region rangesfrom the N-terminus of SEQ ID NO: 64 to the 143rd Serine (S) residue,and the constant region is of the 144th Alanine (A) and the followingresidues. It was predicted by gene sequence prediction software (SignalP ver.2) that the U-chain signal sequence ranges from the N-terminus tothe 19th Cystein (C) of SEQ ID NO: 64. It is thought that the N-terminusof the mature protein is the 20th Glutamic acid (E) of SEQ ID NO: 64.

The translation initiation point of the L-chain DNA is an ATG codon thatbegins from the 59th A from the 5′ end of SEQ ID NO: 65, and thevariable region ranges from the 5′ end to the 445th adenine (A). In theamino acid sequence, the variable region ranges from the N-terminus tothe 129th Lysine (K) of SEQ ID NO: 66. It was predicted by gene sequenceprediction software (Signal P ver.2) that the L-chain signal sequenceranges from the N-terminus to the 22nd Cystein (C) of SEQ ID NO: 66. Itis thought that the N-terminus of the mature protein is the 23rd Asp (D)of SEQ ID NO: 66.

F5-77 H-chain (SEQ ID NO: 63)GGTCTATATAAGCAGAGCTGGGTACGTCCTCACATTCAGTGATCAGCACTGAACACAGACCCGTCGACGGTGATCAGGACTGAACAGAGAGAACTCACCATGGAGTTTGGGCTGAGCTGGCTTTTTCTTGTGGCTATTTTAAAAGGTGTCCAGTGTGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGATGGGGGGTACTATGGTTCGGGGAGTTATGGGTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC F5-77 H-chain amino acid sequence (SEQ IDNO: 64) MEFGLSWLFLVAILKGVQCEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGGYYGSGSYGYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP F5-77 L-chain (SEQ ID NO: 65)CAAGCAGTGGTAACAACGCAGAGTACGCGGGGGGAGTCAGACCCAGTCAGGACACAGCATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTCCTGCTGCTCTGGTTCCCAGGTTCCAGATGCGACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGGATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGGATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATTTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCAACAGGCTAGCAGTTTCCCTCGGACATTCGGCCAAGGGACCAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGA F5-77 L-chain amino acid sequence (SEQ IDNO: 66) MDMRVPAQLLGLLLLWFPGSRCDIQMTQSPSSVSGSVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAGSSLQSGVPSRFSGSGFGTDFTLTISSLQPEDFATYYCQQASSFPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL

Example 18 Expression of Antibody Protein in Animal Cell

The above obtained DNA fragment containing the variable region of theantibody was incorporated into an appropriate vector such as N5KG1 (IDECPharmaceuticals, U.S. Pat. No. 6,001,358), thereby preparing an antibodyexpression vector. As a host cell for expression, for example, CHO-Ras(Katakura Y., et al., Cytotechnology, 31: 103-109, 1999) isappropriately used. The vector can be introduced into the host cell by,for example, electroporation. Approximately 2 μg of the antibodyexpression vector was linearized with a restriction enzyme. The gene wasintroduced into 4×10⁷ CHO-Ras cells under conditions of 350V and 500 μFusing a Bio-Rad electrophoreter, and then inoculated to a 96-wellculture plate. A drug corresponding to the selection marker of theexpression vector was added, and culturing was continued. When colonieswere observed, antibody-expressing lines were selected by the methoddescribed in Example 4. Antibodies can be purified from the selectedcells according to Example 5.

Example 19 Antigen-Specific Antibody Production Suppressive Action ofCD40 Antagonistic Antibody

Mice having a genetic background whereby they were homozygotes for mouseendogenous disrupted CD40 and harboring a transgene of a human CD40 gene(Yasui. et al. Int. Immunol. 2002 Vol 14: 319) were sensitized byintraperitoneally injecting 100 μg (in an amount of NP-CGG) of a complexof 4-hydroxy-3-nitrophenylacetyl-chicken γ-globulin conjugates (NP-CGG:distributed by Hitoshi KIKUTANI, Professor, Research Institute forMicrobial Diseases, Osaka University) and ARAM (ARAM: AntigenRecognition Activation Motif). 30 or 100 μg of each monoclonal antibodywas administered via caudate vein immediately before antigensensitization. 100 μg of anti-human albumin human IgG4 antibody wasadministered as a negative control. 7 days after sensitization, bloodwas collected from the orbital venous plexus, and then the amounts of NPspecific IgG1 and IgM antibodies in sera were measured by the ELISAmethod. The ELISA method was performed by adding NP-bound bovine serumalbumin (NP-BSA: 2.5 μg/ml) (50 μl/well) to each well of a 96-well microplate for ELISA (Maxisorp, Nunc), incubating at 4° C. and then absorbingNP-BSA. Next, the supernatant was discarded, a blocking reagent (SuperBlock, Pierce) was added to each well, and then incubation was performedat room temperature for blocking. Each well was then washed 3 times witha 0.1% Tween20-containing phosphate buffer (PBS-T). Subsequently, eachserum diluted with 10% BlockAce-containing PBS-T was added (50 Ill/well)to each well, followed by incubation at 37° C. for 2 hours for reaction.The microplate was washed 3 times with PBS-T. A solution prepared bydiluting 1.000-fold alkaline phosphatase-labeled goat anti-mouse IgG1 orIgM antibody (COSMO BIO, 1070-04 or 1020-04) with 10%BlockAce-containing PBS-T was added (50 μl/well) to each well, followedby 2 hours of incubation at 37° C. Next, the microplate was washed 3times with PBS-T, a chromogenic substrate solution (50 μl/well,Sigma104, phosphatase substrate) was added to each well, and thenabsorbance at a wavelength of 405 nm was measured with a microplatereader. FIGS. 18 and 19 show the results. In the figures, longitudinalaxes indicate values obtained by conversion using as a unit the serumdiluted 10,000-fold in the case of IgG1 antibody, and the serum diluted100-fold in the case of IgM antibody. Here, the serum was prepared byinjecting NP-CGG twice into C57BL/6 mice, collecting blood from themice, and pooling the serum. Administration of 100 μg each of F4-465,4D11 and KM281-1-10 antibodies strongly suppressed NP-specific IgG1 andIgM antibody production.

Example 20 Proliferation Suppression of Tonsillar B Cells by CD40Antagonistic Antibody

Human tonsils were obtained from Children's Hospital (San Diego, Calif.,U.S.A.). Tonsils were cut into small pieces, minced, and then passedthrough a 70-micrometer nylon mesh cell strainer, thereby preparing acell suspension. The cell suspension was washed several times with PBS,the cell number was counted, and then the suspension was cryopreservedwith 90% human serum (ICN) and 10% DMSO. After thawing, the cells werere-suspended in a standard RPMI medium supplemented with 10% human serumand 2.5 μg/ml amphotericin (fangizon, Gibco/BRL), and then used.

1×10⁵ cells were added to a 96-well plate, and then anti-human CD40antibodies were added at concentrations of 0.01, 0.1, 1.0 and 10 μg/ml.The test was conducted in triplicate at each concentration. 1 μg/mlflag-labeled CD40L (Alexis) and 1 μg/ml CD40L enhancer antibodies(Alexis) were added to each well, followed by 3 days of culturing. Then,1 μCi [³H] thymidine was added to each well. 12 to 15 hours later, thecells were collected, and then the proliferation of tonsillar B cellswas measured using a liquid scintillation counter. The count obtainedwhen B cells had proliferated due to the stimulation of CD40L and noantibody had been added was determined as 100, and the count obtainedwhen no CD40L had been added and B cells had not been not stimulated wasdetermined as 0. For example, when the relative count measured was 30,this was expressed in this experiment as that 70% proliferationinhibition had occurred.

5D12, which is the known antagonistic antibody, did not show more than50% proliferation inhibition even with the antibody concentration of 100μg/ml. F4-465 showed approximately 80% proliferation suppression evenwith the antibody concentration as low as 0.01 μg/ml, and showedapproximately 95% proliferation suppression with an antibodyconcentration of 0.1 to 10 μg/ml (FIG. 20).

All publications, patents and patent applications cited herein areincorporated herein by reference in their entirety.

INDUSTRIAL APPLICABILITY

The present invention provides an antibody against CD40. The antibody ofthe present invention includes both an antibody that acts agonisticallyon CD40 and an antibody that acts antagonistically on CD40. Thus, theseantibodies are useful as, for example, an immunopotentiating agent andimmunosuppressive agent, respectively.

Sequence Listing Free Text

SEQ ID NO: 1: Synthetic DNA SEQ ID NO: 2: Synthetic DNA SEQ ID NO: 3:Synthetic DNA SEQ ID NO: 4: Synthetic DNA SEQ ID NO: 5: Synthetic DNASEQ ID NO: 6: Synthetic DNA SEQ ID NO: 7: Synthetic DNA SEQ ID NO: 8:Synthetic DNA SEQ ID NO: 9: Synthetic DNA SEQ ID NO: 10: Synthetic DNASEQ ID NO: 11: Synthetic DNA SEQ ID NO: 12: Synthetic DNA SEQ ID NO: 13:Synthetic DNA SEQ ID NO: 14: Synthetic DNA SEQ ID NO: 15: Synthetic DNASEQ ID NO: 16: Synthetic DNA SEQ ID NO: 17: Synthetic DNA SEQ ID NO: 18:Synthetic DNA SEQ ID NO: 19: Synthetic DNA SEQ ID NO: 20: Synthetic DNASEQ ID NO: 21: Synthetic DNA SEQ ID NO: 22: Synthetic DNA SEQ ID NO: 23:Synthetic DNA SEQ ID NO: 24: Synthetic DNA SEQ ID NO: 25: Synthetic DNA

SEQ ID NO: 26: Synthetic DNA

1.-30. (canceled)
 31. An antibody or a functional fragment thereof,having the amino acid sequences of a heavy chain variable region and alight chain variable region of an antibody that is produced by, 2105(Accession No: FERM BP-8024) or F1-102 (Accession No: ATCC PTA-3337).32. An antibody or a functional fragment thereof, having amino acidsequences of the mature portions of a heavy chain variable region and alight chain variable region of the antibody produced by a hybridomaF2-103, which are respectively encoded by plasmid DNAs with AccessionNos. ATCC PTA-3302 and ATCC PTA-3303; a heavy chain variable region anda light chain variable region of the antibody produced by a hybridomaF5-77, which are respectively encoded by plasmid DNAs with AccessionNos. ATCC PTA-3304 and ATCC PTA-3305; or a heavy chain variable regionand a light chain variable region of the antibody produced by ahybridoma F5-157, which are respectively encoded by plasmid DNAs withAccession Nos. ATCC PTA-3306 and ATCC PTA-3307.
 33. An antibody or afunctional fragment thereof, having amino acid sequences of the matureportions of a heavy chain variable region and a light chain variableregion of the antibody produced by a hybridoma 2105, which arerespectively represented by SEQ ID NOS: 32 and 34; a heavy chainvariable region and a light chain variable region of the antibodyproduced by a hybridoma 110, which are respectively represented by SEQID NOS: 36 and 38; a heavy chain variable region and a light chainvariable region of the antibody produced by a hybridoma 115, which arerespectively represented by SEQ ID NOS: 40 and 42; a heavy chainvariable region and a light chain variable region of the antibodyproduced by a hybridoma KM643-4-11, which are respectively representedby SEQ ID NOS: 52 and 54; a heavy chain variable region and a lightchain variable region of the antibody produced by a hybridoma F2-103,which are respectively represented by SEQ ID NOS: 60 and 62; or a heavychain variable region and a light chain variable region of the antibodyproduced by a hybridoma F5-77, which are respectively represented by SEQID NOS: 64 and
 66. 34. An antibody or a functional fragment thereof,having amino acid sequences of the mature portions of a heavy chainvariable region and a light chain variable region that are encoded bynucleic acid sequences isolated from a hybridoma 2105, which arerespectively represented by SEQ ID NOS: 31 and 33; a heavy chainvariable region and a light chain variable region that are encoded bynucleic acid sequences isolated from a hybridoma 110, which arerespectively represented by SEQ ID NOS: 35 and 37; a heavy chainvariable region and a light chain variable region that are encoded bynucleic acid sequences isolated from a hybridoma 115, which arerespectively represented by SEQ ID NOS: 39 and 41; a heavy chainvariable region and a light chain variable region that are encoded bynucleic acid sequences isolated from a hybridoma KM643-4-11, which arerespectively represented by SEQ ID NOS: 51 and 53; a heavy chainvariable region and a light chain variable region that are encoded bynucleic acid sequences isolated from a hybridoma F2-103, which arerespectively represented by SEQ ID NOS: 59 and 61; or a heavy chainvariable region and a light chain variable region that are encoded bynucleic acid sequences isolated from a hybridoma F5-77, which arerespectively represented by SEQ ID NOS: 63 and
 65. 35. An antibody or afunctional fragment thereof, having amino acid sequences of a heavychain variable region and a light chain variable region of the antibodyproduced by a hybridoma 2053 or
 285. 36. An antibody or a functionalfragment thereof, having amino acid sequences of a heavy chain variableregion and a light chain variable region of the antibody produced by ahybridoma KM281-1-10 (Accession No: FERM BP-7579), 4D11 (Accession No:FERM BP-7758).
 37. An antibody or a functional fragment thereof, havingamino acid sequences of the mature portions of a heavy chain variableregion and a light chain variable region of the antibody produced by ahybridoma KM281-1-10, which are respectively represented by SEQ ID NOS:44 and 46; a heavy chain variable region and a light chain variableregion of the antibody produced by a hybridoma 4D11, which arerespectively represented by SEQ ID NOS: 48 and
 50. 38. An antibody or afunctional fragment thereof, having amino acid sequences of the matureportions of a heavy chain variable region and a light chain variableregion that are encoded by nucleic acid sequences isolated from ahybridoma KM281-1-10, which are respectively represented by SEQ ID NOS:43 and 45; a heavy chain variable region and a light chain variableregion of an antibody produced by a hybridoma 4D11, which arerespectively represented by SEQ ID NOS: 47 and
 49. 39. An antibody or afunctional fragment thereof, having amino acid sequences of a heavychain variable region and a light chain variable region of the antibodyproduced by a hybridoma KM281-2-10⁻¹-2, 1, KM283-5, KM292-1-24,<M225-2-56, 5H10, 11 E1 or 5G3.
 40. The antibody or the functionalfragment thereof of any one of claims 1 to 9, which is a human antibody.41. A pharmaceutical composition, containing as an active ingredient theantibody or the functional fragment thereof of any one of claims 1 to 9.42. An immunopotentiating agent, anti-tumor agent or anti-autoimmunedisease agent, containing as an active ingredient the antibody or thefunctional fragment thereof of any one of claims 1 to
 5. 43. Animmunosuppressive agent, anti-autoimmune disease agent, therapeuticagent against allergies or therapeutic agent against blood coagulationfactor VIII-inhibiting syndrome, containing as an active ingredient theantibody or the functional fragment thereof of any one of claims 6 to 9.